[sentNum: 1]<Annotation Id="12936" Type="Sentence" StartNode="0" EndNode="43">Committee on Practice Bulletins—Gynecology. PreferredName:Committee SemanticType:[grup] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Gynecologist SemanticType:[prog] POS:NNP POS:IN POS:NN POS:NNP POS:NNP POS:. 
[sentNum: 2]<Annotation Id="12937" Type="Sentence" StartNode="44" EndNode="218">This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology with the assistance of Jennifer Griffin, MD, Mary Gemignani, MD, and Mark Pearlman, MD. PreferredName:Practice Experience SemanticType:[menp] PreferredName:Committee SemanticType:[grup] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Gynecologist SemanticType:[prog] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Massive SemanticType:[qlco] POS:DT POS:NNP POS:NNP POS:VBD POS:VBN POS:IN POS:DT POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:IN POS:DT POS:NN POS:IN POS:NNP POS:NNP POS:, POS:NNP POS:, POS:NNP POS:NNP POS:, POS:NNP POS:, POS:CC POS:NNP POS:NNP POS:, POS:NNP POS:. 
[sentNum: 3]<Annotation Id="12938" Type="Sentence" StartNode="219" EndNode="337">The information is designed to aid practitioners in making decisions about appropriate obstetric and gynecologic care. PreferredName:Information SemanticType:[idcn] PreferredName:Design SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Practitioner SemanticType:[prog] PreferredName:Decision Making SemanticType:[menp] PreferredName:Appropriate SemanticType:[qlco] PreferredName:Obstetrical SemanticType:[ftcn] PreferredName:Gynecologic SemanticType:[spco] PreferredName:care activity SemanticType:[acty] POS:DT POS:NN POS:VBZ POS:VBN POS:TO POS:VB POS:NNS POS:IN POS:VBG POS:NNS POS:IN POS:JJ POS:NN POS:CC POS:JJ POS:NN POS:. 
[sentNum: 4]<Annotation Id="12939" Type="Sentence" StartNode="338" EndNode="438">These guidelines should not be construed as dictating an exclusive course of treatment or procedure. PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Negation SemanticType:[ftcn] PreferredName:Exclusive SemanticType:[idcn] PreferredName:Course SemanticType:[tmco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Interventional procedure SemanticType:[diap, topp] POS:DT POS:NNS POS:MD POS:RB POS:VB POS:VBN POS:IN POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:NN POS:CC POS:NN POS:. 
[sentNum: 5]<Annotation Id="12940" Type="Sentence" StartNode="439" EndNode="598">Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.PreferredName:Variant SemanticType:[qlco] PreferredName:Present SemanticType:[qnco] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Individual SemanticType:[humn] PreferredName:Patient need for (contextual qualifier) SemanticType:[ftcn] PreferredName:Resources SemanticType:[idcn] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Unique SemanticType:[qlco] PreferredName:Health care facility SemanticType:[hcro, mnob] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Practice Experience SemanticType:[menp] POS:NNS POS:IN POS:NN POS:MD POS:VB POS:VBN POS:VBN POS:IN POS:DT POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:, POS:NNS POS:, POS:CC POS:NNS POS:JJ POS:TO POS:DT POS:NN POS:CC POS:NN POS:IN POS:NN POS:. 
[sentNum: 6]<Annotation Id="12941" Type="Sentence" StartNode="600" EndNode="795">Breast cancer is the most commonly diagnosed noncutaneous cancer in women in the United States, and the second leading cause of death from cancer in American women—second only to lung cancer (1). PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Most SemanticType:[qnco] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:United States SemanticType:[geoa] PreferredName:Cause of death.secondary:Find:Pt:^Patient:Nom SemanticType:[clna] PreferredName:Leading SemanticType:[ftcn] PreferredName:From SemanticType:[qlco] PreferredName:American SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Second Primary Cancers SemanticType:[neop] PreferredName:Singular SemanticType:[qnco] PreferredName:Malignant neoplasm of lung SemanticType:[neop] PreferredName:1+ Score SemanticType:[qnco] POS:JJ POS:NN POS:VBZ POS:DT POS:RBS POS:RB POS:JJ POS:NN POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:, POS:CC POS:DT POS:JJ POS:VBG POS:NN POS:IN POS:NN POS:IN POS:NN POS:IN POS:NNP POS:VBD POS:RB POS:TO POS:NN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 7]<Annotation Id="12942" Type="Sentence" StartNode="796" EndNode="865">Breast cancer mortality can be effectively reduced through screening. PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:NN POS:NN POS:NNS POS:MD POS:VB POS:RB POS:VBN POS:IN POS:NN POS:. 
[sentNum: 8]<Annotation Id="12943" Type="Sentence" StartNode="866" EndNode="1084">The purpose of this Practice Bulletin is to review breast cancer screening guidelines and the evidence used to support the recommendations and highlight new screening modalities and controversies surrounding screening.PreferredName:Purpose SemanticType:[ftcn] PreferredName:Practice Experience SemanticType:[menp] PreferredName:To SemanticType:[qlco] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Used by SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Recommendation SemanticType:[idcn] PreferredName:New SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Modality SemanticType:[idcn] PreferredName:controversy SemanticType:[socb] PreferredName:Surrounding (qualifier value) SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:DT POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:VBZ POS:TO POS:VB POS:JJ POS:NN POS:NN POS:NNS POS:CC POS:DT POS:NN POS:VBN POS:TO POS:VB POS:DT POS:NNS POS:CC POS:VB POS:JJ POS:NN POS:NNS POS:CC POS:NNS POS:VBG POS:NN POS:. 
[sentNum: 9]<Annotation Id="12944" Type="Sentence" StartNode="1086" EndNode="1096">BackgroundPreferredName:Background SemanticType:[cnce] POS:NNP 
[sentNum: 10]<Annotation Id="12945" Type="Sentence" StartNode="1098" EndNode="1107">IncidencePreferredName:incidence of cases SemanticType:[ftcn] POS:NNP 
[sentNum: 11]<Annotation Id="12946" Type="Sentence" StartNode="1109" EndNode="1117">Table 1. PreferredName:Table - furniture SemanticType:[mnob] POS:$ POS:CD POS:. 
[sentNum: 12]<Annotation Id="12947" Type="Sentence" StartNode="1118" EndNode="1189">Age-Specific Probabilities of Developing Invasive Female Breast Cancer*PreferredName:Age SemanticType:[orga] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Probability SemanticType:[qnco] PreferredName:Invasive Breast Carcinoma SemanticType:[neop] POS:CD POS:JJ POS:NNPS POS:IN POS:JJ POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP 
[sentNum: 13]<Annotation Id="12948" Type="Sentence" StartNode="1191" EndNode="1209">If Current Age Is… PreferredName:Current age SemanticType:[tmco] POS:IN POS:NNP POS:NNP POS:NNP POS:NNP 
[sentNum: 14]<Annotation Id="12949" Type="Sentence" StartNode="1213" EndNode="1278">The Probability of Developing Breast Cancer in the Next 10 Years†PreferredName:Probability SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Following SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:IN POS:NNP POS:NNP POS:NNP POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:VBZ 
[sentNum: 15]<Annotation Id="12950" Type="Sentence" StartNode="1280" EndNode="1288">Or 1 in:PreferredName:1+ Score SemanticType:[qnco] POS:NN POS:CD POS:IN POS:: 
[sentNum: 16]<Annotation Id="12951" Type="Sentence" StartNode="1290" EndNode="1307">20 	0.06% 	 1,760POS:CD POS:CD POS:. POS:CD POS:NN POS:LS POS:, POS:CD 
[sentNum: 17]<Annotation Id="12952" Type="Sentence" StartNode="1309" EndNode="1323">30 	0.44% 	229POS:CD POS:CD POS:. POS:CD POS:NN POS:JJ 
[sentNum: 18]<Annotation Id="12953" Type="Sentence" StartNode="1325" EndNode="1338">40 	1.44% 	69PreferredName:/40 SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] POS:CD POS:CD POS:. POS:CD POS:NN POS:CD 
[sentNum: 19]<Annotation Id="12954" Type="Sentence" StartNode="1340" EndNode="1353">50 	2.39% 	42POS:CD POS:CD POS:. POS:CD POS:NN POS:JJ 
[sentNum: 20]<Annotation Id="12955" Type="Sentence" StartNode="1355" EndNode="1368">60 	3.40% 	29POS:CD POS:CD POS:. POS:CD POS:NN POS:CD 
[sentNum: 21]<Annotation Id="12956" Type="Sentence" StartNode="1370" EndNode="1383">70 	3.73% 	27POS:CD POS:CD POS:. POS:CD POS:NN POS:CD 
[sentNum: 22]<Annotation Id="12957" Type="Sentence" StartNode="1385" EndNode="1398">Lifetime riskPreferredName:Lifetime Risk SemanticType:[qnco] POS:NN POS:NN 
[sentNum: 23]<Annotation Id="12958" Type="Sentence" StartNode="1400" EndNode="1406">12.08%POS:CD POS:. POS:CD POS:NN 
[sentNum: 24]<Annotation Id="12959" Type="Sentence" StartNode="1409" EndNode="1410">8POS:CD 
[sentNum: 25]<Annotation Id="12960" Type="Sentence" StartNode="1412" EndNode="1477">*Among those free of cancer at the beginning of the age interval. PreferredName:Free (available (qualifier)) SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:At SemanticType:[spco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Interval SemanticType:[tmco] POS:VB POS:IN POS:DT POS:JJ POS:IN POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 26]<Annotation Id="12961" Type="Sentence" StartNode="1478" EndNode="1513">Based on cases diagnosed 2004–2006. PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Diagnosis SemanticType:[fndg] POS:VBN POS:IN POS:NNS POS:VBN POS:CD POS:JJ POS:CD POS:. 
[sentNum: 27]<Annotation Id="12962" Type="Sentence" StartNode="1514" EndNode="1599">Percentages and “1 in” numbers may not be numerically equivalent because of rounding.PreferredName:Percent (qualifier value) SemanticType:[qnco] PreferredName:And SemanticType:[idcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Equal SemanticType:[qlco] PreferredName:Round shape SemanticType:[spco] POS:NNS POS:CC POS:CD POS:CD POS:IN POS:JJ POS:NNS POS:MD POS:RB POS:VB POS:RB POS:JJ POS:IN POS:IN POS:NN POS:. 
[sentNum: 28]<Annotation Id="12963" Type="Sentence" StartNode="1601" EndNode="1663">†Probability derived using NCI DevCan Software, Version 6.4.0.PreferredName:Probability SemanticType:[qnco] PreferredName:Derivation SemanticType:[qlco] PreferredName:Use of SemanticType:[ftcn] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:Computer software SemanticType:[inpr, mnob] PreferredName:Version SemanticType:[ftcn] POS:NNP POS:NNP POS:VBN POS:VBG POS:NNP POS:NNP POS:NNP POS:, POS:CD POS:CD POS:. POS:CD POS:. POS:CD POS:. 
[sentNum: 29]<Annotation Id="12964" Type="Sentence" StartNode="1665" EndNode="1720">Reprinted with permission from American Cancer Society. PreferredName:Reprint SemanticType:[inpr] PreferredName:Authorization documentation SemanticType:[inpr] PreferredName:American Cancer Society SemanticType:[pros] POS:VBN POS:IN POS:NNS POS:IN POS:NNP POS:NNP POS:NNP POS:. 
[sentNum: 30]<Annotation Id="12965" Type="Sentence" StartNode="1721" EndNode="1761">Breast Cancer Facts &amp; Figures 2009–2010. PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:2010s SemanticType:[tmco] POS:NNP POS:NNP POS:NNP POS:CC POS:NNP POS:CD POS:NNP POS:CD POS:. 
[sentNum: 31]<Annotation Id="12966" Type="Sentence" StartNode="1762" EndNode="1800">Atlanta: American Cancer Society, Inc.PreferredName:Atlanta SemanticType:[euka] PreferredName:American Cancer Society SemanticType:[pros] POS:NNP POS:: POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:. 
[sentNum: 32]<Annotation Id="12967" Type="Sentence" StartNode="1802" EndNode="1883">Breast cancer accounts for 27% of all new cases of cancer diagnosed in women (2). PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Account number:Identifier:Point in time:^Patient:Nominal SemanticType:[clna] PreferredName:New SemanticType:[tmco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:2+ Score SemanticType:[qnco] POS:JJ POS:NN POS:VBZ POS:IN POS:CD POS:NN POS:IN POS:DT POS:JJ POS:NNS POS:IN POS:NN POS:VBN POS:IN POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 33]<Annotation Id="12968" Type="Sentence" StartNode="1884" EndNode="1974">A woman's lifetime risk of developing breast cancer is 12.08%, or 1 in 8 (Table 1) (2, 3). PreferredName:Woman SemanticType:[popg] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:2+ Score SemanticType:[qnco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:DT POS:NN POS:NN POS:NN POS:IN POS:VBG POS:NN POS:NN POS:VBZ POS:CD POS:. POS:CD POS:NN POS:, POS:CC POS:CD POS:IN POS:CD POS:( POS:NNP POS:CD POS:) POS:( POS:CD POS:, POS:CD POS:) POS:. POS:POS 
[sentNum: 34]<Annotation Id="12969" Type="Sentence" StartNode="1975" EndNode="2115">In 2010, approximately 207,090 new cases of invasive breast cancer were diagnosed, and 39,840 deaths were attributable to breast cancer (2). PreferredName:2010s SemanticType:[tmco] PreferredName:Approximate SemanticType:[qlco] PreferredName:New SemanticType:[tmco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Invasive SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Attribution SemanticType:[menp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:IN POS:CD POS:, POS:RB POS:CD POS:, POS:CD POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:VBD POS:VBN POS:, POS:CC POS:CD POS:, POS:CD POS:NNS POS:VBD POS:JJ POS:TO POS:NN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 35]<Annotation Id="12970" Type="Sentence" StartNode="2116" EndNode="2197">In addition, 54,010 new cases of in situ breast cancer were reported in 2010 (3). PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:New SemanticType:[tmco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:In situ SemanticType:[spco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Reporting SemanticType:[hlca] PreferredName:2010s SemanticType:[tmco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:IN POS:NN POS:, POS:CD POS:, POS:CD POS:JJ POS:NNS POS:IN POS:IN POS:JJ POS:NN POS:NN POS:VBD POS:VBN POS:IN POS:CD POS:( POS:CD POS:) POS:. 
[sentNum: 36]<Annotation Id="12971" Type="Sentence" StartNode="2198" EndNode="2401">There was a 2% per year decrease in the incidence of breast cancer between 1999 and 2006, possibly reflecting decreased use of menopausal hormone therapy and decreased use of screening mammography (3–5). PreferredName:GPR162 gene SemanticType:[gngm] PreferredName:per year SemanticType:[tmco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Present SemanticType:[qnco] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Possible diagnosis SemanticType:[qlco] PreferredName:Reflecting SemanticType:[menp] PreferredName:Reduced SemanticType:[qlco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Hormone replacement therapy SemanticType:[topp] PreferredName:Reduced SemanticType:[qlco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:3/5 SemanticType:[qnco] POS:EX POS:VBD POS:DT POS:CD POS:NN POS:FW POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:CD POS:CC POS:CD POS:, POS:RB POS:VBG POS:VBN POS:NN POS:IN POS:JJ POS:NN POS:NN POS:CC POS:VBN POS:NN POS:IN POS:NN POS:NN POS:( POS:CD POS:NNP POS:CD POS:) POS:. 
[sentNum: 37]<Annotation Id="12972" Type="Sentence" StartNode="2402" EndNode="2553">Breast cancer-related mortality has been decreasing steadily since 1990, reflecting both earlier detection of breast cancer and improved treatment (3).PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Decreasing SemanticType:[qlco] PreferredName:1990s SemanticType:[tmco] PreferredName:Reflecting SemanticType:[menp] PreferredName:Both SemanticType:[qlco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Improved SemanticType:[qlco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:NN POS:JJ POS:NN POS:VBZ POS:VBN POS:VBG POS:RB POS:IN POS:CD POS:, POS:VBG POS:DT POS:JJR POS:NN POS:IN POS:NN POS:NN POS:CC POS:VBN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 38]<Annotation Id="12973" Type="Sentence" StartNode="2555" EndNode="2615">Components of Breast Cancer Screening and Current GuidelinesPreferredName:Component object SemanticType:[mnob] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] POS:NN POS:IN POS:NNP POS:NNP POS:NNP POS:CC POS:NNP POS:NNS 
[sentNum: 39]<Annotation Id="12974" Type="Sentence" StartNode="2617" EndNode="2840">Breast cancer screening has traditionally included three elements: 1) breast imaging (primarily mammography), 2) clinical breast examination, and 3) patient self-screening (breast self-examination or breast self-awareness). PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Three SemanticType:[qnco] PreferredName:Elements SemanticType:[elii] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:2+ Score SemanticType:[qnco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:Patients SemanticType:[podg] PreferredName:subscriber - self SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] POS:JJ POS:NN POS:NN POS:VBZ POS:RB POS:VBN POS:CD POS:NNS POS:: POS:LS POS:) POS:VBN POS:NN POS:( POS:RB POS:NN POS:) POS:, POS:CD POS:) POS:JJ POS:NN POS:NN POS:, POS:CC POS:LS POS:) POS:VBN POS:NN POS:( POS:JJ POS:NN POS:CC POS:NN POS:NN POS:) POS:. 
[sentNum: 40]<Annotation Id="12975" Type="Sentence" StartNode="2841" EndNode="2970">The relative value of each element and appropriate age of initiation, cessation, and frequency of screening remain controversial. PreferredName:Relative SemanticType:[qlco] PreferredName:Elements SemanticType:[elii] PreferredName:Appropriate SemanticType:[qlco] PreferredName:Age SemanticType:[orga] PreferredName:Initiation SemanticType:[ftcn] PreferredName:Cessation SemanticType:[acty] PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:controversy SemanticType:[socb] POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:CC POS:JJ POS:NN POS:IN POS:CD POS:, POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:VBP POS:JJ POS:. 
[sentNum: 41]<Annotation Id="12976" Type="Sentence" StartNode="2971" EndNode="3060">Table 2 outlines the current screening guidelines of several major medical organizations. PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Outlines (document) SemanticType:[inpr] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Major medical SemanticType:[idcn] PreferredName:Organization administrative structures SemanticType:[orgt] POS:NN POS:CD POS:VBZ POS:DT POS:JJ POS:NN POS:NNS POS:IN POS:JJ POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 42]<Annotation Id="12977" Type="Sentence" StartNode="3061" EndNode="3213">The American College of Obstetricians and Gynecologists (the College) continues to endorse inclusion of all three strategies in breast cancer screening.PreferredName:American College of Obstetricians and Gynecologists SemanticType:[pros] PreferredName:College SemanticType:[mnob] PreferredName:Continuous SemanticType:[idcn] PreferredName:Inclusion SemanticType:[qlco] PreferredName:Three SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:DT POS:NNP POS:NNP POS:IN POS:NNP POS:CC POS:NNP POS:( POS:DT POS:NNP POS:) POS:VBZ POS:TO POS:VB POS:NN POS:IN POS:DT POS:CD POS:NNS POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 43]<Annotation Id="12978" Type="Sentence" StartNode="3215" EndNode="3223">Table 2. PreferredName:Table - furniture SemanticType:[mnob] POS:$ POS:CD POS:. 
[sentNum: 44]<Annotation Id="12979" Type="Sentence" StartNode="3224" EndNode="3263">Breast Cancer Screening RecommendationsPreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Screening for cancer SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] POS:NNP POS:NNP POS:NNP POS:NNP 
[sentNum: 45]<Annotation Id="12980" Type="Sentence" StartNode="3268" EndNode="3368">Mammography 	Clinical Breast Examination 	Breast Self-Examination Instruction 	Breast Self-AwarenessPOS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:JJ POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP 
[sentNum: 46]<Annotation Id="12981" Type="Sentence" StartNode="3370" EndNode="3454">American College of Obstetricians and Gynecologists 	Age 40 years and older annually PreferredName:American College of Obstetricians and Gynecologists SemanticType:[pros] PreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] POS:NNP POS:NNP POS:IN POS:NNPS POS:CC POS:NNP POS:NNP POS:CD POS:NNS POS:CC POS:JJR POS:RB 
[sentNum: 47]<Annotation Id="12982" Type="Sentence" StartNode="3458" EndNode="3489">Age 20-39 years every 1-3 yearsPreferredName:year SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:year SemanticType:[tmco] POS:NN POS:CD POS:: POS:CD POS:NNS POS:DT POS:CD POS:: POS:CD POS:NNS 
[sentNum: 48]<Annotation Id="12983" Type="Sentence" StartNode="3491" EndNode="3522">Consider for high-risk patientsPreferredName:consider SemanticType:[idcn] PreferredName:High risk of SemanticType:[qlco] PreferredName:Patients SemanticType:[podg] POS:VBN POS:IN POS:JJ POS:NNS 
[sentNum: 49]<Annotation Id="12984" Type="Sentence" StartNode="3524" EndNode="3535">RecommendedPreferredName:Recommendation SemanticType:[idcn] POS:NNS 
[sentNum: 50]<Annotation Id="12985" Type="Sentence" StartNode="3537" EndNode="3568">Age 40 years and older annuallyPreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] POS:VB POS:CD POS:NNS POS:CC POS:JJR POS:RB 
[sentNum: 51]<Annotation Id="12986" Type="Sentence" StartNode="3570" EndNode="3626">American Cancer Society 	Age 40 years and older annually PreferredName:American Cancer Society SemanticType:[pros] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] POS:NNP POS:NNP POS:NNP POS:NNP POS:CD POS:NNS POS:CC POS:JJR POS:RB 
[sentNum: 52]<Annotation Id="12987" Type="Sentence" StartNode="3630" EndNode="3661">Age 20-39 years every 1-3 yearsPreferredName:year SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:year SemanticType:[tmco] POS:NN POS:CD POS:: POS:CD POS:NNS POS:DT POS:CD POS:: POS:CD POS:NNS 
[sentNum: 53]<Annotation Id="12988" Type="Sentence" StartNode="3663" EndNode="3698">Optional for age 20 years and olderPreferredName:Optional SemanticType:[qlco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] POS:VB POS:IN POS:NN POS:CD POS:NNS POS:CC POS:JJR 
[sentNum: 54]<Annotation Id="12989" Type="Sentence" StartNode="3700" EndNode="3711">RecommendedPreferredName:Recommendation SemanticType:[idcn] POS:NNS 
[sentNum: 55]<Annotation Id="12990" Type="Sentence" StartNode="3713" EndNode="3744">Age 40 years and older annuallyPreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] POS:VB POS:CD POS:NNS POS:CC POS:JJR POS:RB 
[sentNum: 56]<Annotation Id="12991" Type="Sentence" StartNode="3746" EndNode="3816">National Comprehensive Cancer Network 	Age 40 years and older annually PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:CD POS:NNS POS:CC POS:JJR POS:RB 
[sentNum: 57]<Annotation Id="12992" Type="Sentence" StartNode="3820" EndNode="3851">Age 20-39 years every 1-3 yearsPreferredName:year SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:year SemanticType:[tmco] POS:NN POS:CD POS:: POS:CD POS:NNS POS:DT POS:CD POS:: POS:CD POS:NNS 
[sentNum: 58]<Annotation Id="12993" Type="Sentence" StartNode="3853" EndNode="3864">RecommendedPreferredName:Recommendation SemanticType:[idcn] POS:NNS 
[sentNum: 59]<Annotation Id="12994" Type="Sentence" StartNode="3866" EndNode="3877">RecommendedPreferredName:Recommendation SemanticType:[idcn] POS:NNS 
[sentNum: 60]<Annotation Id="12995" Type="Sentence" StartNode="3879" EndNode="3910">Age 40 years and older annuallyPreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Senility SemanticType:[fndg] PreferredName:Annual SemanticType:[tmco] POS:VB POS:CD POS:NNS POS:CC POS:JJR POS:RB 
[sentNum: 61]<Annotation Id="12996" Type="Sentence" StartNode="3912" EndNode="3990">National Cancer Institute 	Age 40 years and older every 1-2 years 	Recommended PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Phase I/II Trial SemanticType:[resa] PreferredName:year SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] POS:NNP POS:NNP POS:NNP POS:NNP POS:CD POS:NNS POS:CC POS:JJR POS:DT POS:CD POS:: POS:CD POS:NNS POS:JJ 
[sentNum: 62]<Annotation Id="12997" Type="Sentence" StartNode="3994" EndNode="4009">Not RecommendedPreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] POS:NNPS POS:NNP 
[sentNum: 63]<Annotation Id="12998" Type="Sentence" StartNode="4011" EndNode="4012">—POS:NNP 
[sentNum: 64]<Annotation Id="12999" Type="Sentence" StartNode="4014" EndNode="4102">U.S. Preventative Services Task Force 	Age 50-74 years biennially 	Insufficient evidence PreferredName:United States SemanticType:[geoa] PreferredName:Services SemanticType:[ocac] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] POS:NNP POS:. POS:NNP POS:. POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:CD POS:: POS:CD POS:NNS POS:JJ POS:JJ POS:NN 
[sentNum: 65]<Annotation Id="13000" Type="Sentence" StartNode="4106" EndNode="4121">Not RecommendedPreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] POS:NNPS POS:NNP 
[sentNum: 66]<Annotation Id="13001" Type="Sentence" StartNode="4123" EndNode="4124">—POS:NNP 
[sentNum: 67]<Annotation Id="13002" Type="Sentence" StartNode="4126" EndNode="4147">Screening MammographyPreferredName:Screening mammography SemanticType:[topp] POS:NNP POS:NNP 
[sentNum: 68]<Annotation Id="13003" Type="Sentence" StartNode="4149" EndNode="4185">Rationale for Mammographic ScreeningPreferredName:Indication of (contextual qualifier) SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] POS:VBN POS:IN POS:NNP POS:NNP 
[sentNum: 69]<Annotation Id="13004" Type="Sentence" StartNode="4187" EndNode="4360">Tumors detected at an early stage that are small and confined to the breast are more likely to be successfully treated, with a 98% 5-year survival for localized disease (3). PreferredName:Neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Early SemanticType:[tmco] PreferredName:Stage SemanticType:[qlco] PreferredName:Small SemanticType:[qnco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:More SemanticType:[ftcn] PreferredName:Probably SemanticType:[idcn] PreferredName:Treating SemanticType:[ftcn] PreferredName:With - dosing instruction fragment SemanticType:[inpr] PreferredName:per year SemanticType:[tmco] PreferredName:Continuance of life SemanticType:[acty] PreferredName:Localized SemanticType:[spco] PreferredName:N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide SemanticType:[orch] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:NNS POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:WDT POS:VBP POS:JJ POS:CC POS:VBN POS:TO POS:DT POS:NN POS:VBP POS:RBR POS:JJ POS:TO POS:VB POS:RB POS:VBN POS:, POS:IN POS:DT POS:CD POS:NN POS:CD POS:: POS:NN POS:NN POS:IN POS:VBN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 70]<Annotation Id="13005" Type="Sentence" StartNode="4361" EndNode="4527">After 18 years of follow-up, one initial study found that 89% of tumors measuring 1 cm or less were cured by primary surgery (mastectomy and axillary dissection) (6). PreferredName:Status post SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Follow-Up Studies SemanticType:[resa] PreferredName:One SemanticType:[qnco] PreferredName:Initially SemanticType:[tmco] PreferredName:Present SemanticType:[qnco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Measured SemanticType:[qlco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Less Than SemanticType:[inpr] PreferredName:Cure (remedy) SemanticType:[cnce] PreferredName:Primary operation SemanticType:[topp] PreferredName:Mastectomy SemanticType:[topp] PreferredName:Excision of axillary lymph nodes SemanticType:[topp] POS:IN POS:CD POS:NNS POS:IN POS:NN POS:, POS:CD POS:JJ POS:NN POS:VBD POS:IN POS:CD POS:NN POS:IN POS:NNS POS:VBG POS:CD POS:NNS POS:CC POS:JJR POS:VBD POS:VBN POS:IN POS:JJ POS:NN POS:( POS:NN POS:CC POS:JJ POS:NN POS:) POS:( POS:CD POS:) POS:. 
[sentNum: 71]<Annotation Id="13006" Type="Sentence" StartNode="4528" EndNode="4835">Other studies have confirmed these results, with 90% of patients experiencing 10-year (or longer) disease-free survival periods after tumors measuring 1 cm or less were detected by mammography, indicating the likelihood that the tumors had not yet metastasized before they were diagnosed and treated (7–11).PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Confirmation SemanticType:[idcn] PreferredName:Result SemanticType:[ftcn] PreferredName:With - dosing instruction fragment SemanticType:[inpr] PreferredName:&lt;90 SemanticType:[qnco] PreferredName:Patients SemanticType:[podg] PreferredName:Practice Experience SemanticType:[menp] PreferredName:per year SemanticType:[tmco] PreferredName:Long SemanticType:[qlco] PreferredName:Disease-Free Survival SemanticType:[qnco] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Measured SemanticType:[qlco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Less Than SemanticType:[inpr] PreferredName:Detection SemanticType:[topp] PreferredName:Mammography SemanticType:[diap] PreferredName:Probability SemanticType:[qnco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Negation SemanticType:[ftcn] PreferredName:Neoplasm Metastasis SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Treating SemanticType:[ftcn] POS:JJ POS:NNS POS:VBP POS:VBN POS:DT POS:NNS POS:, POS:IN POS:CD POS:NN POS:IN POS:NNS POS:VBG POS:CD POS:: POS:NN POS:( POS:CC POS:JJR POS:) POS:JJ POS:NN POS:NNS POS:IN POS:NNS POS:VBG POS:CD POS:NNS POS:CC POS:JJR POS:VBD POS:VBN POS:IN POS:NN POS:, POS:VBG POS:DT POS:NN POS:IN POS:DT POS:NNS POS:VBD POS:RB POS:RB POS:VBN POS:IN POS:PRP POS:VBD POS:VBN POS:CC POS:VBN POS:( POS:CD POS:NNS POS:CD POS:) POS:. 
[sentNum: 72]<Annotation Id="13007" Type="Sentence" StartNode="4837" EndNode="5051">By mathematical estimation, a typical ductal adenocarcinoma with a constant mean doubling time of 100 days would have been present for more than 11 years before it grew to a generally palpable size of 2 cm (12–14). PreferredName:Mathematics SemanticType:[ocdi] PreferredName:Estimated SemanticType:[qnco] PreferredName:Usual SemanticType:[qlco] PreferredName:Ductal Breast Carcinoma SemanticType:[neop] PreferredName:Constant (qualifier) SemanticType:[qlco] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Duplicate SemanticType:[ftcn] PreferredName:Temporal periods of day SemanticType:[tmco] PreferredName:Presentation SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Palpable SemanticType:[qlco] PreferredName:size SemanticType:[spco] POS:IN POS:JJ POS:NN POS:, POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:JJ POS:NN POS:NN POS:IN POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:JJ POS:IN POS:JJR POS:IN POS:CD POS:NNS POS:IN POS:PRP POS:VBD POS:TO POS:DT POS:RB POS:JJ POS:NN POS:IN POS:CD POS:NN POS:( POS:CD POS:NNS POS:CD POS:) POS:. 
[sentNum: 73]<Annotation Id="13008" Type="Sentence" StartNode="5052" EndNode="5230">Mammography screening could potentially identify a nonpalpable mass measuring approximately 1 mm to 1 cm during its preclinical phase, 3 years before it becomes palpable (12–15). PreferredName:Screening mammography SemanticType:[topp] PreferredName:Mass of body structure SemanticType:[fndg] PreferredName:Measured SemanticType:[qlco] PreferredName:Approximate SemanticType:[qlco] PreferredName:PFDN5 gene SemanticType:[gngm] PreferredName:Preclinical SemanticType:[qlco] PreferredName:Phase SemanticType:[tmco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Palpable SemanticType:[qlco] POS:JJ POS:NN POS:MD POS:RB POS:VB POS:DT POS:JJ POS:NN POS:VBG POS:RB POS:CD POS:NN POS:TO POS:CD POS:NN POS:IN POS:PRP$ POS:JJ POS:NN POS:, POS:CD POS:NNS POS:IN POS:PRP POS:VBZ POS:JJ POS:( POS:CD POS:NNS POS:CD POS:) POS:. 
[sentNum: 74]<Annotation Id="13009" Type="Sentence" StartNode="5231" EndNode="5383">This concept is commonly referred to as sojourn time, which is the time interval when cancer may be detected by screening before it becomes symptomatic. PreferredName:concept SemanticType:[idcn] PreferredName:Referral placed SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Time Interval SemanticType:[tmco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Symptomatic SemanticType:[ftcn] POS:DT POS:NN POS:VBZ POS:RB POS:VBN POS:TO POS:RB POS:JJ POS:NN POS:, POS:WDT POS:VBZ POS:DT POS:NN POS:NN POS:WRB POS:NN POS:MD POS:VB POS:VBN POS:IN POS:NN POS:IN POS:PRP POS:VBZ POS:JJ POS:. 
[sentNum: 75]<Annotation Id="13010" Type="Sentence" StartNode="5384" EndNode="5521">The sojourn time of an individual type of cancer varies, with more biologically aggressive tumors typically having shorter sojourn times. PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Individual SemanticType:[humn] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Varies SemanticType:[inpr] PreferredName:More SemanticType:[ftcn] PreferredName:biological SemanticType:[qlco] PreferredName:Aggressive course SemanticType:[tmco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Short SemanticType:[qnco] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] POS:DT POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:VBZ POS:, POS:IN POS:RBR POS:JJ POS:JJ POS:NNS POS:RB POS:VBG POS:JJR POS:JJ POS:NNS POS:. 
[sentNum: 76]<Annotation Id="13011" Type="Sentence" StartNode="5522" EndNode="5596">The greatest predictor of sojourn time in breast cancer appears to be age. PreferredName:Most SemanticType:[qnco] PreferredName:Predictor SemanticType:[idcn] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Appearance SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Age SemanticType:[orga] POS:DT POS:JJS POS:NN POS:IN POS:CD POS:NN POS:IN POS:NN POS:NN POS:VBZ POS:TO POS:VB POS:NN POS:. 
[sentNum: 77]<Annotation Id="13012" Type="Sentence" StartNode="5597" EndNode="5820">Estimates of mean sojourn time for breast cancer in women increase with age: for ages 40–49 years, mean sojourn time is 2–2.4 years; 50–59 years, 2.5–3.7 years; 60–69 years, 3.5–4.2 years; and 70–74 years, 4–4.1 years (16).PreferredName:Estimated SemanticType:[qnco] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Increase SemanticType:[ftcn] PreferredName:Age SemanticType:[orga] PreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:2+ Score SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:2/5 SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:3/5 SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:VB POS:IN POS:NN POS:: POS:IN POS:NNS POS:CD POS:NNS POS:CD POS:NNS POS:, POS:VBP POS:NN POS:NN POS:VBZ POS:CD POS:NNS POS:CD POS:. POS:CD POS:NNS POS:: POS:CD POS:JJ POS:CD POS:NNS POS:, POS:CD POS:. POS:CD POS:NNP POS:CD POS:. POS:CD POS:NNS POS:: POS:CD POS:JJ POS:CD POS:NNS POS:, POS:CD POS:. POS:CD POS:NNP POS:CD POS:. POS:CD POS:NNS POS:: POS:CC POS:CD POS:JJ POS:CD POS:NNS POS:, POS:CD POS:NNP POS:CD POS:. POS:CD POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 78]<Annotation Id="13013" Type="Sentence" StartNode="5822" EndNode="5957">The mean sojourn time has implications for breast cancer screening because it is desirable to detect tumors during this sojourn period. PreferredName:Population Mean SemanticType:[qnco] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Period (temporal qualifier) SemanticType:[tmco] POS:DT POS:JJ POS:JJ POS:NN POS:VBZ POS:NNS POS:IN POS:NN POS:NN POS:NN POS:IN POS:PRP POS:VBZ POS:JJ POS:TO POS:VB POS:NNS POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 79]<Annotation Id="13014" Type="Sentence" StartNode="5958" EndNode="6180">Individuals who are likely to have types of cancer with shorter sojourn times are more likely to benefit from more frequent screening when compared with those with slow-growing tumors that have a larger preclinical window. PreferredName:Individual SemanticType:[humn] PreferredName:Probably SemanticType:[idcn] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Short SemanticType:[qnco] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Probably SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Frequent SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Slow SemanticType:[qlco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Large SemanticType:[qnco] PreferredName:Preclinical SemanticType:[qlco] PreferredName:Interval SemanticType:[tmco] POS:NNS POS:WP POS:VBP POS:JJ POS:TO POS:VB POS:NNS POS:IN POS:NN POS:IN POS:JJR POS:NN POS:NNS POS:VBP POS:RBR POS:JJ POS:TO POS:VB POS:IN POS:JJR POS:JJ POS:NN POS:WRB POS:VBN POS:IN POS:DT POS:IN POS:JJ POS:NNS POS:WDT POS:VBP POS:DT POS:JJR POS:JJ POS:NN POS:. 
[sentNum: 80]<Annotation Id="13015" Type="Sentence" StartNode="6181" EndNode="6370">Screening strategies should be designed to maximize the likelihood of detecting the cancer during the preclinical window, when treatment options may be greater and outcomes may be improved.PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Design SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Probability SemanticType:[qnco] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Preclinical SemanticType:[qlco] PreferredName:Interval SemanticType:[tmco] PreferredName:treatment options SemanticType:[topp] PreferredName:Greater SemanticType:[qnco] PreferredName:Result SemanticType:[ftcn] PreferredName:Improved SemanticType:[qlco] POS:JJ POS:NNS POS:MD POS:VB POS:VBN POS:TO POS:VB POS:DT POS:NN POS:IN POS:VBG POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:, POS:WRB POS:NN POS:NNS POS:MD POS:VB POS:JJR POS:CC POS:NNS POS:MD POS:VB POS:VBN POS:. 
[sentNum: 81]<Annotation Id="13016" Type="Sentence" StartNode="6372" EndNode="6397">Evaluation of MammographyPreferredName:Evaluation procedure SemanticType:[hlca] PreferredName:Mammography SemanticType:[diap] POS:NNS POS:IN POS:NNP 
[sentNum: 82]<Annotation Id="13017" Type="Sentence" StartNode="6399" EndNode="6592">A recent meta-analysis conducted for the United States Preventive Services Task Force reviewed eight randomized controlled trials of mammographic screening conducted between 1986 and 2006 (17). PreferredName:Recent SemanticType:[tmco] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Behavior SemanticType:[inbe] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Eight SemanticType:[qnco] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Behavior SemanticType:[inbe] POS:DT POS:JJ POS:NNS POS:VBN POS:IN POS:DT POS:NNP POS:NNPS POS:NNP POS:NNP POS:NNP POS:NNP POS:VBN POS:CD POS:JJ POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:VBN POS:IN POS:CD POS:CC POS:CD POS:( POS:CD POS:) POS:. 
[sentNum: 83]<Annotation Id="13018" Type="Sentence" StartNode="6593" EndNode="6848">Despite some study limitations (all studies were rated of “fair” quality by the United States Preventive Services Task Force), this review reaffirmed a reduction in breast cancer-related mortality for women aged 39–69 years who were invited for screening. PreferredName:Study SemanticType:[resa] PreferredName:Limitation SemanticType:[ftcn] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Fair (qualifier) SemanticType:[qlco] PreferredName:Quality SemanticType:[qlco] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:IN POS:DT POS:NN POS:NNS POS:( POS:DT POS:NNS POS:VBD POS:VBN POS:IN POS:VBG POS:JJ POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:) POS:, POS:DT POS:NN POS:VBD POS:DT POS:NN POS:IN POS:NN POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:JJ POS:CD POS:NNS POS:WP POS:VBD POS:VBN POS:IN POS:NN POS:. 
[sentNum: 84]<Annotation Id="13019" Type="Sentence" StartNode="6849" EndNode="6945">This is consistent with the mortality reductions demonstrated in previous meta-analyses (18–22).PreferredName:Consistent with SemanticType:[idcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Previous SemanticType:[tmco] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:18/22 SemanticType:[qnco] POS:DT POS:VBZ POS:JJ POS:IN POS:DT POS:NN POS:NNS POS:VBN POS:IN POS:JJ POS:NNS POS:( POS:CD POS:NNP POS:CD POS:) POS:. 
[sentNum: 85]<Annotation Id="13020" Type="Sentence" StartNode="6947" EndNode="7125">Relative risk of breast cancer mortality in women invited for screening was 0.85 for women aged 39–49 years; 0.86 for women aged 50–59 years; and 0.68 for women aged 60–69 years. PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Arabic numeral 68 SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:NNS POS:VBN POS:IN POS:NN POS:VBD POS:CD POS:. POS:CD POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:: POS:CD POS:. POS:CD POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:: POS:CC POS:CD POS:. POS:CD POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:. 
[sentNum: 86]<Annotation Id="13021" Type="Sentence" StartNode="7126" EndNode="7233">Evidence was insufficient to demonstrate a mortality reduction for women aged 70 years and older (Table 3). PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Table - furniture SemanticType:[mnob] POS:NN POS:VBD POS:JJ POS:TO POS:VB POS:DT POS:NN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 87]<Annotation Id="13022" Type="Sentence" StartNode="7234" EndNode="7462">However, because of the increasing incidence of breast cancer as women age, more young women (aged 39–49 years) had to be invited for screening to prevent one breast cancer-related death when compared with older women (Table 3). PreferredName:increasing incidence SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:More SemanticType:[ftcn] PreferredName:Young SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Age-Years SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:One SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Comparison SemanticType:[acty] PreferredName:Old SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Table - furniture SemanticType:[mnob] POS:RB POS:, POS:RB POS:IN POS:DT POS:VBG POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:NN POS:, POS:JJR POS:JJ POS:NNS POS:( POS:VBN POS:CD POS:NNP POS:CD POS:NNS POS:) POS:VBD POS:TO POS:VB POS:VBN POS:IN POS:VBG POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:WRB POS:VBN POS:IN POS:JJR POS:NNS POS:( POS:CD POS:CD POS:) POS:. 
[sentNum: 88]<Annotation Id="13023" Type="Sentence" StartNode="7463" EndNode="7693">The number needed to invite for screening (over several rounds of screening and at least 11 years of follow-up) to prevent one breast cancer death in women aged 39–49 years was 1,904, compared with 1,339 in women aged 50–59 years. PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Over (spatial) SemanticType:[spco] PreferredName:Round shape SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:And SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:One SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Comparison SemanticType:[acty] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:VBN POS:TO POS:VB POS:IN POS:NN POS:( POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:CC POS:IN POS:JJS POS:CD POS:NNS POS:IN POS:NN POS:) POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:VBD POS:CD POS:, POS:VB POS:, POS:VBN POS:IN POS:CD POS:, POS:CD POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:. 
[sentNum: 89]<Annotation Id="13024" Type="Sentence" StartNode="7694" EndNode="7951">This difference in number needed to invite for screening to prevent one death was a key reason the United States Preventive Services Task Force elected not to recommend routine screening for women aged 40–49 years, despite similar mortality reductions (23).PreferredName:This SemanticType:[euka] PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:One SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Indication of (contextual qualifier) SemanticType:[idcn] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Routine SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Similarity SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Arabic numeral 23 SemanticType:[qnco] POS:DT POS:NN POS:IN POS:NN POS:VBN POS:TO POS:VB POS:IN POS:VBG POS:TO POS:VB POS:CD POS:NN POS:VBD POS:DT POS:JJ POS:NN POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:VBD POS:RB POS:TO POS:VB POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:, POS:IN POS:JJ POS:NN POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 90]<Annotation Id="13025" Type="Sentence" StartNode="7953" EndNode="7961">Table 3. PreferredName:Table - furniture SemanticType:[mnob] POS:NNP POS:NNP POS:. 
[sentNum: 91]<Annotation Id="13026" Type="Sentence" StartNode="7962" EndNode="8058">Pooled Relative Risks for Breast Cancer Mortality From Mammography Screening Trials for All AgesPreferredName:Pool (action) SemanticType:[ftcn] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:From SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Age SemanticType:[orga] POS:NNP POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:IN POS:DT POS:NNPS 
[sentNum: 92]<Annotation Id="13027" Type="Sentence" StartNode="8060" EndNode="8083">Age 	Trials Included, n PreferredName:Age SemanticType:[orga] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] POS:NNP POS:NNP POS:NNP POS:, POS:RB 
[sentNum: 93]<Annotation Id="13028" Type="Sentence" StartNode="8087" EndNode="8127">RR for Breast Cancer Mortality (95% CrI)PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Costa Rica SemanticType:[geoa] POS:NNP POS:IN POS:NN POS:NNP POS:NNP POS:( POS:CD POS:NN POS:NNP POS:) 
[sentNum: 94]<Annotation Id="13029" Type="Sentence" StartNode="8129" EndNode="8175">NNI to Prevent 1 Breast Cancer Death (95% CrI)PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Costa Rica SemanticType:[geoa] POS:VB POS:TO POS:NNP POS:CD POS:NNP POS:NNP POS:NNP POS:( POS:CD POS:NN POS:NNP POS:) 
[sentNum: 95]<Annotation Id="13030" Type="Sentence" StartNode="8177" EndNode="8184">39-49 y POS:CD POS:: POS:CD POS:NN 
[sentNum: 96]<Annotation Id="13031" Type="Sentence" StartNode="8188" EndNode="8190">8*POS:CD POS:NN 
[sentNum: 97]<Annotation Id="13032" Type="Sentence" StartNode="8192" EndNode="8208">0.85 (0.75–0.96)POS:CD POS:. POS:CD POS:( POS:RB POS:. POS:CD POS:NN POS:CD POS:. POS:CD POS:) 
[sentNum: 98]<Annotation Id="13033" Type="Sentence" StartNode="8210" EndNode="8225">1904 (929–6378)POS:NNP POS:( POS:CD POS:NNS POS:CD POS:) 
[sentNum: 99]<Annotation Id="13034" Type="Sentence" StartNode="8227" EndNode="8234">50-59 y POS:CD POS:: POS:JJ POS:NNS 
[sentNum: 100]<Annotation Id="13035" Type="Sentence" StartNode="8238" EndNode="8240">6†POS:CD POS:NN 
[sentNum: 101]<Annotation Id="13036" Type="Sentence" StartNode="8242" EndNode="8258">0.86 (0.75–0.99)POS:CD POS:. POS:CD POS:( POS:RB POS:. POS:CD POS:NN POS:CD POS:. POS:CD POS:) 
[sentNum: 102]<Annotation Id="13037" Type="Sentence" StartNode="8260" EndNode="8275">1339 (322–7455)POS:CD POS:( POS:CD POS:NNS POS:CD POS:) 
[sentNum: 103]<Annotation Id="13038" Type="Sentence" StartNode="8277" EndNode="8284">60-69 y PreferredName:Arabic numeral 69 SemanticType:[inpr] POS:CD POS:: POS:CD POS:NN 
[sentNum: 104]<Annotation Id="13039" Type="Sentence" StartNode="8288" EndNode="8290">2‡POS:CD POS:NN 
[sentNum: 105]<Annotation Id="13040" Type="Sentence" StartNode="8292" EndNode="8308">0.68 (0.54–0.87)PreferredName:Arabic numeral 68 SemanticType:[inpr] POS:NNP POS:. POS:NN POS:( POS:CD POS:. POS:CD POS:NNP POS:CD POS:. POS:CD POS:) 
[sentNum: 106]<Annotation Id="13041" Type="Sentence" StartNode="8310" EndNode="8324">377 (230–1050)POS:CD POS:( POS:CD POS:NNS POS:CD POS:) 
[sentNum: 107]<Annotation Id="13042" Type="Sentence" StartNode="8326" EndNode="8333">70-74 y POS:CD POS:: POS:CD POS:NN 
[sentNum: 108]<Annotation Id="13043" Type="Sentence" StartNode="8337" EndNode="8339">1§POS:CD POS:NN 
[sentNum: 109]<Annotation Id="13044" Type="Sentence" StartNode="8341" EndNode="8357">1.12 (0.73–1.72)PreferredName:1+ Score SemanticType:[qnco] POS:CD POS:. POS:CD POS:( POS:RB POS:. POS:CD POS:NN POS:CD POS:. POS:CD POS:) 
[sentNum: 110]<Annotation Id="13045" Type="Sentence" StartNode="8359" EndNode="8372">Not availablePreferredName:Not available SemanticType:[idcn] POS:JJ POS:JJ 
[sentNum: 111]<Annotation Id="13046" Type="Sentence" StartNode="8374" EndNode="8484">Abbreviations: CrI, credible interval; NNI, number needed to invite to screening; RR, relative risk; y, years.PreferredName:Abbreviations SemanticType:[inpr] PreferredName:Costa Rica SemanticType:[geoa] PreferredName:credibility SemanticType:[qlco] PreferredName:Interval SemanticType:[tmco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:year SemanticType:[tmco] POS:NNS POS:: POS:NNP POS:, POS:JJ POS:NN POS:: POS:NNP POS:, POS:NN POS:VBN POS:TO POS:VB POS:TO POS:NN POS:: POS:NNP POS:, POS:JJ POS:NN POS:: POS:NN POS:, POS:NNS POS:. 
[sentNum: 112]<Annotation Id="13047" Type="Sentence" StartNode="8486" EndNode="8661">*Health Insurance Plan of Greater New York, Canadian National Breast Screening Study-1, Stockholm, Malmö, Swedish Two-County trial (2 trials), Gothenburg trial, and Age trial.PreferredName:health insurance plan SemanticType:[inpr] PreferredName:Greater SemanticType:[qnco] PreferredName:New York (geographic location) SemanticType:[geoa] PreferredName:CANADIAN SemanticType:[fndg] PreferredName:National citizen SemanticType:[inpr] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Screening Study SemanticType:[resa] PreferredName:Swedish SemanticType:[popg] PreferredName:Two SemanticType:[qnco] PreferredName:County SemanticType:[geoa] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:2+ Score SemanticType:[qnco] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Age SemanticType:[orga] PreferredName:Clinical Trials SemanticType:[resa] POS:NNP POS:NNP POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:CD POS:, POS:NNP POS:, POS:NNP POS:, POS:NNP POS:NNP POS:NNP POS:NN POS:( POS:CD POS:NNS POS:) POS:, POS:NNP POS:NN POS:, POS:CC POS:NN POS:NN POS:. 
[sentNum: 113]<Annotation Id="13048" Type="Sentence" StartNode="8663" EndNode="8784">†Canadian National Breast Screening Study-1, Stockholm, Malmö, Swedish Two-County trial (2 trials), and Gothenburg trial.PreferredName:CANADIAN SemanticType:[fndg] PreferredName:National citizen SemanticType:[inpr] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Screening Study SemanticType:[resa] PreferredName:Swedish SemanticType:[popg] PreferredName:Two SemanticType:[qnco] PreferredName:County SemanticType:[geoa] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:2+ Score SemanticType:[qnco] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Clinical Trials SemanticType:[resa] POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:VBZ POS:CD POS:, POS:NNP POS:, POS:CD POS:, POS:NNP POS:NNP POS:NNP POS:NN POS:( POS:CD POS:NNS POS:) POS:, POS:CC POS:NNP POS:NN POS:. 
[sentNum: 114]<Annotation Id="13049" Type="Sentence" StartNode="8786" EndNode="8837">‡Malmö and Swedish Two-County trial (Östergötland).PreferredName:Swedish SemanticType:[popg] PreferredName:Two SemanticType:[qnco] PreferredName:County SemanticType:[geoa] PreferredName:Clinical Trials SemanticType:[resa] POS:JJ POS:NNS POS:CC POS:NNP POS:NNP POS:NNP POS:NN POS:( POS:NNP POS:) POS:. 
[sentNum: 115]<Annotation Id="13050" Type="Sentence" StartNode="8839" EndNode="8880">§Swedish Two-County trial (Östergötland).PreferredName:Swedish SemanticType:[popg] PreferredName:Two SemanticType:[qnco] PreferredName:County SemanticType:[geoa] PreferredName:Clinical Trials SemanticType:[resa] POS:JJ POS:JJ POS:NNP POS:NNP POS:NN POS:( POS:NN POS:) POS:. 
[sentNum: 116]<Annotation Id="13051" Type="Sentence" StartNode="8882" EndNode="9057">Reprinted with permission from Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. PreferredName:Reprint SemanticType:[inpr] PreferredName:Authorization documentation SemanticType:[inpr] PreferredName:Potassium Ion SemanticType:[elii, phsu] PreferredName:KNG1 gene SemanticType:[gngm] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Update SemanticType:[tmco] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] POS:VBN POS:IN POS:NN POS:IN POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:. POS:NNP POS:IN POS:NN POS:NN POS:: POS:DT POS:NN POS:IN POS:DT POS:NNP POS:. POS:NNP POS:. POS:NNP POS:NNP POS:NNP POS:NNP POS:. 
[sentNum: 117]<Annotation Id="13052" Type="Sentence" StartNode="9058" EndNode="9089">Ann Intern Med 2009;151:727–37.PreferredName:Intern SemanticType:[prog] POS:NNP POS:NNP POS:NN POS:CD POS:: POS:NNP POS:: POS:CD POS:NNP POS:CD POS:. 
[sentNum: 118]<Annotation Id="13053" Type="Sentence" StartNode="9091" EndNode="9380">Because of differences in study design, with most randomized clinical trials evaluating biennial mammographic screening, these randomized controlled trials do not provide meaningful comparisons between different screening strategies in terms of age at initiation, cessation, and frequency. PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:Research Design SemanticType:[resa] PreferredName:Clinical Trials, Randomized SemanticType:[inpr, resa] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Negation SemanticType:[ftcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Meaning SemanticType:[idcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Different SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Term (temporal) SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Initiation SemanticType:[ftcn] PreferredName:Cessation SemanticType:[acty] PreferredName:Frequencies (time pattern) SemanticType:[tmco] POS:IN POS:IN POS:NNS POS:IN POS:NN POS:NN POS:, POS:IN POS:RBS POS:JJ POS:JJ POS:NNS POS:VBG POS:JJ POS:JJ POS:NN POS:, POS:DT POS:JJ POS:JJ POS:NNS POS:VBP POS:RB POS:VB POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:NNS POS:IN POS:NNS POS:IN POS:NN POS:IN POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:. 
[sentNum: 119]<Annotation Id="13054" Type="Sentence" StartNode="9381" EndNode="9611">The lack of clear evidence on this issue led the United States Preventive Services Task Force to commission the creation of screening models that could compare different strategies to help guide national screening recommendations. PreferredName:Lacking SemanticType:[qlco] PreferredName:Clear SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Problem SemanticType:[fndg] PreferredName:Light Emitting Diode Device Component SemanticType:[mnob] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Creation SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Model SemanticType:[inpr] PreferredName:Comparison SemanticType:[acty] PreferredName:Different SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Professional guide SemanticType:[prog] PreferredName:National citizen SemanticType:[inpr] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NN POS:VBD POS:DT POS:NNP POS:NNPS POS:NNP POS:NNP POS:NNP POS:NNP POS:TO POS:VB POS:DT POS:NN POS:IN POS:NN POS:NNS POS:WDT POS:MD POS:VB POS:JJ POS:NNS POS:TO POS:VB POS:NN POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 120]<Annotation Id="13055" Type="Sentence" StartNode="9612" EndNode="9783">These six models were created by independent investigative groups that are a part of the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network. PreferredName:Six SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] PreferredName:Created By SemanticType:[qlco] PreferredName:Independence SemanticType:[idcn] PreferredName:Groups SemanticType:[idcn] PreferredName:Part of SemanticType:[spco] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Surveillance Modeling SemanticType:[resa] PreferredName:Consortium or Network SemanticType:[prog] POS:DT POS:CD POS:NNS POS:VBD POS:VBN POS:IN POS:JJ POS:JJ POS:NNS POS:WDT POS:VBP POS:DT POS:NN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:CC POS:NNP POS:NNP POS:NNP POS:. POS:POS 
[sentNum: 121]<Annotation Id="13056" Type="Sentence" StartNode="9784" EndNode="10030">These models were created using a common set of age-specific variables, with the goal of identifying efficient screening strategies (ie, those that produce a gain in mortality reduction or a gain in life years per additional screening mammogram).PreferredName:Model SemanticType:[inpr] PreferredName:Creation SemanticType:[acty] PreferredName:Use of SemanticType:[ftcn] PreferredName:Common (qualifier value) SemanticType:[qnco] PreferredName:Set scale SemanticType:[ftcn] PreferredName:Age SemanticType:[orga] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Variable (uniformity) SemanticType:[qlco] PreferredName:With - dosing instruction fragment SemanticType:[inpr] PreferredName:objective (goal) SemanticType:[inpr] PreferredName:Efficient SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Gain SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Gain SemanticType:[qnco] PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] POS:DT POS:NNS POS:VBD POS:VBN POS:VBG POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:, POS:IN POS:DT POS:NN POS:IN POS:VBG POS:JJ POS:NN POS:NNS POS:( POS:NNP POS:, POS:DT POS:WDT POS:VBP POS:DT POS:NN POS:IN POS:NN POS:NN POS:CC POS:DT POS:NN POS:IN POS:NN POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:) POS:. 
[sentNum: 122]<Annotation Id="13057" Type="Sentence" StartNode="10032" EndNode="10214">Biennial screening was used in seven of eight screening strategies found to be efficient in reducing mortality, and in six of these eight strategies, screening began at age 50 years. PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Use of SemanticType:[ftcn] PreferredName:Seven SemanticType:[qnco] PreferredName:Eight SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Present SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Efficient SemanticType:[qlco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:And SemanticType:[idcn] PreferredName:Six SemanticType:[qnco] PreferredName:Eight SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] POS:JJ POS:NN POS:VBD POS:VBN POS:IN POS:CD POS:IN POS:CD POS:NN POS:NNS POS:VBN POS:TO POS:VB POS:JJ POS:IN POS:VBG POS:NN POS:, POS:CC POS:IN POS:CD POS:IN POS:DT POS:CD POS:NNS POS:, POS:NN POS:VBD POS:IN POS:NN POS:CD POS:NNS POS:. 
[sentNum: 123]<Annotation Id="13058" Type="Sentence" StartNode="10215" EndNode="10399">A review of the strategies concluded that more lives could be saved by extending screening to women older than 69 years, rather than extending screening to women aged 40–49 years (24). PreferredName:Act Class - review SemanticType:[idcn] PreferredName:strategy SemanticType:[menp] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:More SemanticType:[ftcn] PreferredName:% live SemanticType:[qlco] PreferredName:Commit Operation SemanticType:[mcha] PreferredName:Extent SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Extent SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:IN POS:DT POS:NNS POS:VBD POS:IN POS:JJR POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:VBG POS:NN POS:TO POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:, POS:RB POS:IN POS:VBG POS:NN POS:TO POS:NNS POS:VBN POS:CD POS:JJ POS:CD POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 124]<Annotation Id="13059" Type="Sentence" StartNode="10400" EndNode="10547">However, when defining benefit as number of life years gained through screening, screening was started at age 40 years in four of eight strategies. PreferredName:Benefits SemanticType:[qnco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Gain SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Age Started SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Present SemanticType:[qnco] PreferredName:Four SemanticType:[qnco] PreferredName:Eight SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] POS:RB POS:, POS:WRB POS:VBG POS:NN POS:IN POS:NN POS:IN POS:NN POS:NNS POS:VBD POS:IN POS:NN POS:, POS:NN POS:VBD POS:VBN POS:IN POS:NN POS:CD POS:NNS POS:IN POS:CD POS:IN POS:CD POS:NNS POS:. 
[sentNum: 125]<Annotation Id="13060" Type="Sentence" StartNode="10548" EndNode="10734">Although annual screening was an efficient strategy for reducing breast cancer mortality and increasing life years gained, it was noted by the authors to be more resource intensive (24).PreferredName:annual screening SemanticType:[diap] PreferredName:Efficient SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Reduced SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Gain SemanticType:[qnco] PreferredName:Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider} SemanticType:[clna] PreferredName:Journalist SemanticType:[prog] PreferredName:More SemanticType:[ftcn] PreferredName:Resources SemanticType:[idcn] POS:IN POS:JJ POS:NN POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:NN POS:CC POS:VBG POS:NN POS:NNS POS:VBD POS:, POS:PRP POS:VBD POS:VBN POS:IN POS:DT POS:NNS POS:TO POS:VB POS:JJR POS:NN POS:JJ POS:( POS:CD POS:) POS:. 
[sentNum: 126]<Annotation Id="13061" Type="Sentence" StartNode="10736" EndNode="10760">Other Imaging TechniquesPreferredName:Imaging Techniques SemanticType:[diap] POS:JJ POS:NN POS:NNS 
[sentNum: 127]<Annotation Id="13062" Type="Sentence" StartNode="10762" EndNode="10845">Ultrasonography is an established adjunct to mammography in the imaging evaluation. PreferredName:Ultrasonography SemanticType:[diap] PreferredName:Accepted SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Evaluation procedure SemanticType:[hlca] POS:NNP POS:VBZ POS:DT POS:JJ POS:NN POS:TO POS:NN POS:IN POS:DT POS:NN POS:NN POS:. 
[sentNum: 128]<Annotation Id="13063" Type="Sentence" StartNode="10846" EndNode="11094">It is useful in evaluating inconclusive mammographic findings, in evaluating young patients and other women with dense breast tissue, in guiding tissue core-needle biopsy and other biopsy techniques, and in differentiating a cyst from a solid mass. PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Indeterminate SemanticType:[idcn] PreferredName:Mammography finding SemanticType:[fndg] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Young SemanticType:[tmco] PreferredName:Patients SemanticType:[podg] PreferredName:Other SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Dense SemanticType:[qlco] PreferredName:Breast tissue sample SemanticType:[bpoc] PreferredName:Professional guide SemanticType:[prog] PreferredName:Body tissue SemanticType:[tisu] PreferredName:Core needle biopsy SemanticType:[diap] PreferredName:Method of biopsy SemanticType:[hlca] PreferredName:And SemanticType:[idcn] PreferredName:Well Differentiated SemanticType:[qlco] PreferredName:Mass of body structure SemanticType:[fndg] PreferredName:Cyst SemanticType:[dsyn] PreferredName:Solid SemanticType:[qlco] POS:PRP POS:VBZ POS:JJ POS:IN POS:VBG POS:JJ POS:JJ POS:NNS POS:, POS:IN POS:VBG POS:JJ POS:NNS POS:CC POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:, POS:IN POS:VBG POS:NN POS:JJ POS:NN POS:CC POS:JJ POS:NN POS:NNS POS:, POS:CC POS:IN POS:VBG POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 129]<Annotation Id="13064" Type="Sentence" StartNode="11095" EndNode="11195">It is not recommended as a screening modality for women at average risk of developing breast cancer. PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Diagnostic Radiology Modality SemanticType:[diap] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:PRP POS:VBZ POS:RB POS:VBN POS:IN POS:DT POS:NN POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:. 
[sentNum: 130]<Annotation Id="13065" Type="Sentence" StartNode="11196" EndNode="11439">Ultrasonography may be an option for additional screening in women at high risk who are candidates for magnetic resonance imaging (MRI) screening but cannot receive MRI because of gadolinium contrast allergy, claustrophobia, or other barriers.PreferredName:Ultrasonography SemanticType:[diap] PreferredName:option - ActMoodPredicate SemanticType:[idcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Present SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:High risk of SemanticType:[qlco] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Receive SemanticType:[qlco] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Gadolinium SemanticType:[elii, irda] PreferredName:Contrast SemanticType:[qlco] PreferredName:History of allergies SemanticType:[fndg] PreferredName:Claustrophobia SemanticType:[mobd] PreferredName:BARRIER SemanticType:[medd] POS:NNP POS:MD POS:VB POS:DT POS:NN POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:WP POS:VBP POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:( POS:NNP POS:) POS:NN POS:CC POS:VB POS:NNP POS:RB POS:IN POS:NN POS:NN POS:NN POS:, POS:NN POS:, POS:CC POS:JJ POS:NNS POS:. POS:MD POS:RB 
[sentNum: 131]<Annotation Id="13066" Type="Sentence" StartNode="11441" EndNode="11661">Magnetic resonance imaging can be a useful adjunct to diagnostic mammography, but cost, duration of the examination, and injection of contrast material prohibit its use as a routine, population-based screening technique. PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:diagnostic use SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:Financial cost SemanticType:[qnco] PreferredName:Duration (temporal concept) SemanticType:[tmco] PreferredName:Injection procedure SemanticType:[topp] PreferredName:Contrast Media SemanticType:[irda] PreferredName:Prohibit SemanticType:[carb, imft, phsu] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Routine SemanticType:[qlco] PreferredName:geographic population SemanticType:[qnco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Screening Method SemanticType:[inpr] POS:JJ POS:NN POS:NN POS:MD POS:VB POS:DT POS:JJ POS:JJ POS:TO POS:JJ POS:NN POS:, POS:CC POS:NN POS:, POS:NN POS:IN POS:DT POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:NN POS:VBP POS:PRP$ POS:NN POS:IN POS:DT POS:JJ POS:, POS:JJ POS:NN POS:NN POS:. 
[sentNum: 132]<Annotation Id="13067" Type="Sentence" StartNode="11662" EndNode="11770">The American Cancer Society has issued guidelines regarding the use of MRI for screening in high-risk women. PreferredName:American Cancer Society SemanticType:[pros] PreferredName:Problem SemanticType:[fndg] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Use of SemanticType:[ftcn] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:High risk of SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] POS:DT POS:NNP POS:NNP POS:NNP POS:VBZ POS:VBN POS:NNS POS:VBG POS:DT POS:NN POS:IN POS:NNP POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:. 
[sentNum: 133]<Annotation Id="13068" Type="Sentence" StartNode="11771" EndNode="11980">Based on expert panel review of the evidence, the American Cancer Society recommends MRI screening for women with a 20% or greater lifetime risk of developing breast cancer, including women with the following:PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Study Section SemanticType:[prog] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Greater SemanticType:[qnco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Followed by SemanticType:[tmco] POS:VBN POS:IN POS:NN POS:NN POS:NN POS:IN POS:DT POS:NN POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:VBZ POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:DT POS:CD POS:NN POS:CC POS:JJR POS:NN POS:NN POS:IN POS:VBG POS:NN POS:NN POS:, POS:VBG POS:NNS POS:IN POS:DT POS:NN POS:: 
[sentNum: 134]<Annotation Id="13069" Type="Sentence" StartNode="11986" EndNode="12027">Have a known BRCA1 or BRCA2 gene mutationPreferredName:Known SemanticType:[qlco] PreferredName:BRCA2 Gene Mutation SemanticType:[comd] POS:VB POS:DT POS:JJ POS:NNP POS:CD POS:CC POS:NNP POS:CD POS:NN POS:NN 
[sentNum: 135]<Annotation Id="13070" Type="Sentence" StartNode="12033" EndNode="12137">Have a first-degree relative with a BRCA1 or BRCA2 gene mutation and have not had any testing themselvesPreferredName:First Degree Relative SemanticType:[famg] PreferredName:BRCA2 Gene Mutation SemanticType:[comd] PreferredName:Negation SemanticType:[ftcn] PreferredName:Testing SemanticType:[ftcn] POS:VB POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:CD POS:CC POS:NN POS:CD POS:NN POS:NN POS:CC POS:VBP POS:RB POS:VBN POS:DT POS:NN POS:PRP 
[sentNum: 136]<Annotation Id="13071" Type="Sentence" StartNode="12143" EndNode="12269">A lifetime risk of breast cancer of 20% or greater, according to risk assessment tools that are based mainly on family historyPreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Greater SemanticType:[qnco] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Scientific Equipment SemanticType:[mnob] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Family History Domain SemanticType:[idcn] POS:DT POS:NN POS:NN POS:IN POS:NN POS:NN POS:IN POS:CD POS:NN POS:CC POS:JJR POS:, POS:VBG POS:TO POS:NN POS:NN POS:NNS POS:WDT POS:VBP POS:VBN POS:RB POS:IN POS:NN POS:NN 
[sentNum: 137]<Annotation Id="13072" Type="Sentence" StartNode="12275" EndNode="12360">A history of radiation therapy to the chest between the ages of 10 years and 30 yearsPreferredName:History of radiation therapy SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:Anterior thoracic region SemanticType:[blor] PreferredName:Age-Years SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:IN POS:NN POS:NN POS:TO POS:DT POS:NN POS:IN POS:DT POS:NNS POS:IN POS:CD POS:NNS POS:CC POS:CD POS:NNS 
[sentNum: 138]<Annotation Id="13073" Type="Sentence" StartNode="12366" EndNode="12529">Other genetic syndromes, including Li–Fraumeni syndrome, Cowden syndrome, or Bannayan–Riley–Ruvalcaba syndrome or one of these syndromes in a first-degree relativePreferredName:Genetic syndrome SemanticType:[dsyn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Lithium Cation SemanticType:[elii] PreferredName:Syndrome SemanticType:[dsyn] PreferredName:Hamartoma Syndrome, Multiple SemanticType:[neop] PreferredName:Ruvalcaba Syndrome SemanticType:[cgab] PreferredName:One SemanticType:[qnco] PreferredName:Adverse Event Associated with Syndromes SemanticType:[fndg] PreferredName:First Degree Relative SemanticType:[famg] POS:JJ POS:JJ POS:NNS POS:, POS:VBG POS:NNP POS:NNP POS:NN POS:, POS:JJ POS:NN POS:, POS:CC POS:CD POS:JJ POS:NNP POS:NN POS:CC POS:CD POS:IN POS:DT POS:NNS POS:IN POS:DT POS:JJ POS:NN 
[sentNum: 139]<Annotation Id="13074" Type="Sentence" StartNode="12531" EndNode="12771">The panel concluded that there was insufficient evidence to recommend for or against MRI screening for women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mammography (25). PreferredName:Groups SemanticType:[idcn] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Personal Attribute SemanticType:[orga] PreferredName:History of malignant neoplasm of breast SemanticType:[fndg] PreferredName:Carcinoma in Situ SemanticType:[neop] PreferredName:Atypical hyperplasia SemanticType:[patf] PreferredName:Mammographic breast density SemanticType:[fndg] POS:DT POS:NN POS:VBD POS:IN POS:EX POS:VBD POS:JJ POS:NN POS:TO POS:VB POS:IN POS:CC POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:, POS:NN POS:IN POS:NN POS:, POS:JJ POS:NN POS:, POS:CC POS:RB POS:JJ POS:NNS POS:IN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 140]<Annotation Id="13075" Type="Sentence" StartNode="12772" EndNode="12866">Breast MRI is not recommended for screening women at average risk of developing breast cancer.PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:At risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:NNP POS:NNP POS:VBZ POS:RB POS:VBN POS:IN POS:VBG POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:. 
[sentNum: 141]<Annotation Id="13076" Type="Sentence" StartNode="12868" EndNode="13116">Color Doppler ultrasonography, computer-aided detection, positron emission tomography, scintimammography, and digital breast tomosynthesis have shown promise in selected clinical situations or as adjuncts to mammography for breast cancer diagnosis. PreferredName:Ultrasonography, Doppler, Color SemanticType:[diap] PreferredName:Computers SemanticType:[mnob] PreferredName:Helping Behavior SemanticType:[socb] PreferredName:Detection SemanticType:[topp] PreferredName:Positron-Emission Tomography SemanticType:[diap] PreferredName:Scintimammography SemanticType:[diap] PreferredName:Digital breast tomosynthesis SemanticType:[diap] PreferredName:Show SemanticType:[inpr] PreferredName:promise SemanticType:[idcn] PreferredName:Choose (action) SemanticType:[acty] PreferredName:Clinical SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Breast Carcinoma SemanticType:[neop] POS:NNP POS:NNP POS:NNP POS:, POS:JJ POS:NN POS:, POS:NN POS:NN POS:NN POS:, POS:NN POS:, POS:CC POS:JJ POS:NN POS:NNS POS:VBP POS:VBN POS:NN POS:IN POS:VBN POS:JJ POS:NNS POS:CC POS:IN POS:NNS POS:TO POS:NN POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 142]<Annotation Id="13077" Type="Sentence" StartNode="13117" EndNode="13200">However, these technologies are not considered alternatives to routine mammography.PreferredName:Technology SemanticType:[ocdi] PreferredName:Negation SemanticType:[ftcn] PreferredName:consider SemanticType:[idcn] PreferredName:Alternative SemanticType:[cnce] PreferredName:Routine SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] POS:RB POS:, POS:DT POS:NNS POS:VBP POS:RB POS:VBN POS:NNS POS:TO POS:JJ POS:NN POS:. 
[sentNum: 143]<Annotation Id="13078" Type="Sentence" StartNode="13202" EndNode="13221">Digital MammographyPreferredName:Digital Mammography SemanticType:[diap] POS:NNP POS:NNP 
[sentNum: 144]<Annotation Id="13079" Type="Sentence" StartNode="13223" EndNode="13315">In 2005, the results of the Digital Mammographic Imaging Screening Trial were reported (26). PreferredName:Digital X-ray SemanticType:[inpr] PreferredName:Mammography finding SemanticType:[fndg] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Screening Study SemanticType:[resa] PreferredName:Reporting SemanticType:[hlca] POS:IN POS:CD POS:, POS:DT POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:VBD POS:VBN POS:( POS:CD POS:) POS:. 
[sentNum: 145]<Annotation Id="13080" Type="Sentence" StartNode="13316" EndNode="13435">During the 2-year study period, 49,528 women were recruited to the study from 33 sites in the United States and Canada. PreferredName:2+ Score SemanticType:[qnco] PreferredName:per year SemanticType:[tmco] PreferredName:Study SemanticType:[resa] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Study SemanticType:[resa] PreferredName:From SemanticType:[qlco] PreferredName:Site SemanticType:[spco] PreferredName:United States SemanticType:[geoa] PreferredName:Canada SemanticType:[geoa] POS:IN POS:DT POS:CD POS:JJ POS:NN POS:NN POS:NN POS:, POS:CD POS:, POS:JJ POS:NNS POS:VBD POS:VBN POS:TO POS:DT POS:NN POS:IN POS:CD POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:CC POS:NNP POS:. 
[sentNum: 146]<Annotation Id="13081" Type="Sentence" StartNode="13436" EndNode="13525">All participants underwent both digital mammography and film mammography in random order. PreferredName:Participant SemanticType:[popg] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Randomization SemanticType:[resa] PreferredName:Order (action) SemanticType:[acty] POS:DT POS:NNS POS:VBD POS:DT POS:JJ POS:NN POS:CC POS:NN POS:NN POS:IN POS:JJ POS:NN POS:. 
[sentNum: 147]<Annotation Id="13082" Type="Sentence" StartNode="13526" EndNode="13635">The diagnostic accuracy of digital mammography and film mammography was similar across the entire population. PreferredName:Diagnostic Accuracy SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Similarity SemanticType:[qlco] PreferredName:Entire SemanticType:[qnco] PreferredName:geographic population SemanticType:[qnco] POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:CC POS:NN POS:NN POS:VBD POS:JJ POS:IN POS:DT POS:JJ POS:NN POS:. 
[sentNum: 148]<Annotation Id="13083" Type="Sentence" StartNode="13636" EndNode="13825">Digital mammography was superior to film mammography in women younger than 50 years, women with heterogeneously dense or extremely dense breasts, and premenopausal and perimenopausal women.PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Upper SemanticType:[spco] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Dense SemanticType:[qlco] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Premenopausal - menopausal status SemanticType:[tmco] PreferredName:Perimenopausal SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] POS:NNP POS:NN POS:VBD POS:JJ POS:TO POS:NN POS:NN POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:, POS:NNS POS:IN POS:RB POS:JJ POS:CC POS:RB POS:JJ POS:NNS POS:, POS:CC POS:JJ POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 149]<Annotation Id="13084" Type="Sentence" StartNode="13827" EndNode="13903">In 2007, the follow-up and final results of the Oslo II study were reported. PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:End-stage SemanticType:[tmco] PreferredName:research outcome SemanticType:[fndg] PreferredName:Reporting SemanticType:[hlca] POS:IN POS:NNP POS:, POS:DT POS:NN POS:CC POS:JJ POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:NN POS:VBD POS:VBN POS:. 
[sentNum: 150]<Annotation Id="13085" Type="Sentence" StartNode="13904" EndNode="14051">This was a randomized trial of screen-film versus full-field digital mammography in a population-based screening program of women aged 45–69 years. PreferredName:Clinical Trials, Randomized SemanticType:[inpr, resa] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Full field SemanticType:[spco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Population Programs SemanticType:[hlca] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] POS:DT POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:NN POS:IN POS:JJ POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:NN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:. 
[sentNum: 151]<Annotation Id="13086" Type="Sentence" StartNode="14052" EndNode="14176">In this trial, women aged 45–69 years were assigned to undergo film mammography (n=16,985) or digital mammography (n=6,944). PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:PersonNameUse - assigned SemanticType:[inpr] PreferredName:To SemanticType:[qlco] PreferredName:Film Mammography SemanticType:[diap] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] POS:IN POS:DT POS:NN POS:, POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:VBD POS:VBN POS:TO POS:VB POS:NN POS:NN POS:( POS:JJ POS:NNP POS:CD POS:, POS:CD POS:) POS:CC POS:JJ POS:NN POS:( POS:JJ POS:NNP POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 152]<Annotation Id="13087" Type="Sentence" StartNode="14177" EndNode="14307">The group of women aged 45–49 years was monitored for 1.5 years and the group of women aged 50–69 years was monitored for 2 years. PreferredName:Women's Groups SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Preventive monitoring SemanticType:[hlca] PreferredName:year SemanticType:[tmco] PreferredName:Women's Groups SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Preventive monitoring SemanticType:[hlca] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:VBD POS:VBN POS:IN POS:LS POS:. POS:CD POS:NNS POS:CC POS:DT POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CD POS:NNS POS:VBD POS:VBN POS:IN POS:CD POS:NNS POS:. 
[sentNum: 153]<Annotation Id="13088" Type="Sentence" StartNode="14308" EndNode="14462">There was a significant difference in the cancer detection rate between the digital mammography (0.59%) and film mammography (0.38%) (P=0.02) groups (27).PreferredName:Statistical Significance SemanticType:[qnco] PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:Cancer Detection SemanticType:[hlca] PreferredName:Rate SemanticType:[qnco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Film Mammography SemanticType:[diap] PreferredName:P prime SemanticType:[clna] PreferredName:Groups SemanticType:[idcn] POS:EX POS:VBD POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:IN POS:DT POS:JJ POS:NN POS:( POS:NNP POS:. POS:CD POS:NN POS:) POS:CC POS:NN POS:NN POS:( POS:NNP POS:. POS:CD POS:NN POS:) POS:( POS:NNP POS:NNPS POS:NNP POS:. POS:CD POS:) POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 154]<Annotation Id="13089" Type="Sentence" StartNode="14464" EndNode="14694">A recent meta-analysis of data from eight large randomized studies found that, overall, digital mammography demonstrated a slightly higher detection rate than film mammography, particularly for women aged 60 years or younger (28).PreferredName:Recent SemanticType:[tmco] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Data SemanticType:[idcn] PreferredName:Eight SemanticType:[qnco] PreferredName:Large SemanticType:[qnco] PreferredName:Randomization SemanticType:[resa] PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Present SemanticType:[qnco] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Slightly SemanticType:[idcn] PreferredName:High SemanticType:[qlco] PreferredName:Detection SemanticType:[topp] PreferredName:Rate SemanticType:[qnco] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Young SemanticType:[tmco] POS:DT POS:JJ POS:NNS POS:IN POS:NNS POS:IN POS:CD POS:JJ POS:JJ POS:NNS POS:VBD POS:IN POS:, POS:JJ POS:, POS:JJ POS:NN POS:VBD POS:DT POS:RB POS:JJR POS:NN POS:NN POS:IN POS:NN POS:NN POS:, POS:RB POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:( POS:CD POS:) POS:. 
[sentNum: 155]<Annotation Id="13090" Type="Sentence" StartNode="14696" EndNode="14739">Clinical Considerations and RecommendationsPreferredName:Clinical SemanticType:[qlco] PreferredName:consideration SemanticType:[fndg] PreferredName:Recommendation SemanticType:[idcn] POS:NN POS:NNS POS:CC POS:NNPS 
[sentNum: 156]<Annotation Id="13091" Type="Sentence" StartNode="14745" EndNode="14869">What is the difference between breast self-examination and breast self-awareness, and are these screening methods effective?PreferredName:Menopause SemanticType:[phsf] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Effective SemanticType:[qlco] POS:WP POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:NN POS:CC POS:NN POS:NN POS:, POS:CC POS:VBP POS:DT POS:NN POS:NNS POS:JJ POS:. 
[sentNum: 157]<Annotation Id="13092" Type="Sentence" StartNode="14871" EndNode="15035">Breast self-examination is the performance of an examination of the breasts in a consistent, systematic way by the individual on a regular basis, typically monthly. PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Performance SemanticType:[inbe] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Present SemanticType:[qnco] PreferredName:Consistent with SemanticType:[idcn] PreferredName:systematic SemanticType:[ftcn] PreferredName:Individual SemanticType:[humn] PreferredName:Regular SemanticType:[qlco] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:per month (qualifier value) SemanticType:[tmco] POS:JJ POS:NN POS:VBZ POS:DT POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNS POS:IN POS:DT POS:JJ POS:, POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NN POS:, POS:RB POS:JJ POS:. 
[sentNum: 158]<Annotation Id="13093" Type="Sentence" StartNode="15036" EndNode="15211">Historically, physicians have been encouraged to educate their patients on how to perform these examinations, and public awareness campaigns have focused on this intervention. PreferredName:Physicians SemanticType:[prog] PreferredName:To SemanticType:[qlco] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Patients SemanticType:[podg] PreferredName:Performed SemanticType:[ftcn] PreferredName:Physical Examination SemanticType:[hlca] PreferredName:prevention through information dissemination SemanticType:[topp] PreferredName:Focal SemanticType:[spco] PreferredName:Intervention regimes SemanticType:[hlca] POS:NNP POS:, POS:NNS POS:VBP POS:VBN POS:VBN POS:TO POS:VB POS:PRP$ POS:NNS POS:IN POS:WRB POS:TO POS:VB POS:DT POS:NNS POS:, POS:CC POS:JJ POS:NN POS:NNS POS:VBP POS:VBN POS:IN POS:DT POS:NN POS:. 
[sentNum: 159]<Annotation Id="13094" Type="Sentence" StartNode="15212" EndNode="15329">It still may be appropriate for certain high-risk populations and for other women who choose to follow this approach.PreferredName:Appropriate SemanticType:[qlco] PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:High Risk Populations SemanticType:[popg] PreferredName:And SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Choose (action) SemanticType:[acty] PreferredName:To SemanticType:[qlco] PreferredName:Followed by SemanticType:[tmco] PreferredName:Approach SemanticType:[spco] POS:PRP POS:RB POS:MD POS:VB POS:JJ POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:IN POS:JJ POS:NNS POS:WP POS:VBP POS:TO POS:VB POS:DT POS:NN POS:. 
[sentNum: 160]<Annotation Id="13095" Type="Sentence" StartNode="15331" EndNode="15451">Currently, there is an evolution away from teaching breast self-examination toward the concept of breast self-awareness. PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Biological Evolution SemanticType:[genf] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:concept SemanticType:[idcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] POS:RB POS:, POS:EX POS:VBZ POS:DT POS:NN POS:RB POS:IN POS:VBG POS:NN POS:NN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 161]<Annotation Id="13096" Type="Sentence" StartNode="15452" EndNode="15660">The College, the American Cancer Society, and the National Comprehensive Cancer Network endorse breast self-awareness, which is defined as women's awareness of the normal appearance and feel of their breasts. PreferredName:College SemanticType:[mnob] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Definition SemanticType:[cnce] PreferredName:Woman SemanticType:[popg] PreferredName:Awareness SemanticType:[menp] PreferredName:Normal tissue morphology SemanticType:[fndg] PreferredName:Emotions SemanticType:[menp] PreferredName:Breast SemanticType:[bpoc] POS:DT POS:NNP POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:VBP POS:NN POS:NN POS:, POS:WDT POS:VBZ POS:VBN POS:IN POS:NNS POS:NN POS:IN POS:DT POS:JJ POS:NN POS:CC POS:NN POS:IN POS:PRP$ POS:NNS POS:. POS:POS 
[sentNum: 162]<Annotation Id="13097" Type="Sentence" StartNode="15661" EndNode="15921">This concept has arisen because approximately one half of all cases of breast cancer in women 50 years and older and more than 70% of cases of cancer in women younger than 50 years are detected by women themselves, frequently as an incidental finding (29, 30). PreferredName:concept SemanticType:[idcn] PreferredName:Approximate SemanticType:[qlco] PreferredName:One SemanticType:[qnco] PreferredName:Half SemanticType:[qnco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:More SemanticType:[ftcn] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Detection SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Frequent SemanticType:[tmco] PreferredName:Incidental Findings SemanticType:[fndg] POS:DT POS:NN POS:VBZ POS:VBN POS:IN POS:RB POS:CD POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NN POS:NN POS:IN POS:NNS POS:CD POS:NNS POS:CC POS:JJR POS:CC POS:JJR POS:IN POS:CD POS:NN POS:IN POS:NNS POS:IN POS:NN POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:VBP POS:VBN POS:IN POS:NNS POS:PRP POS:, POS:RB POS:IN POS:DT POS:JJ POS:NN POS:( POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 163]<Annotation Id="13098" Type="Sentence" StartNode="15922" EndNode="16050">In addition, the effectiveness of self-examination was at odds with what was anticipated based on the aforementioned statistics.PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Self Efficacy SemanticType:[menp] PreferredName:Wiskott-Aldrich Syndrome SemanticType:[dsyn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Science of Statistics SemanticType:[ocdi] POS:IN POS:NN POS:, POS:DT POS:NN POS:IN POS:NN POS:VBD POS:IN POS:NNS POS:IN POS:WP POS:VBD POS:VBN POS:VBN POS:IN POS:DT POS:JJ POS:NNS POS:. 
[sentNum: 164]<Annotation Id="13099" Type="Sentence" StartNode="16052" EndNode="16135">Breast self-awareness should be encouraged and can include breast self-examination. PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Include (action) SemanticType:[acty] PreferredName:Breast Self-Examination SemanticType:[diap] POS:NN POS:NN POS:MD POS:VB POS:VBN POS:CC POS:MD POS:VB POS:NN POS:NN POS:. 
[sentNum: 165]<Annotation Id="13100" Type="Sentence" StartNode="16136" EndNode="16329">Women who desire to perform self-examination as a part of this breast self-awareness strategy may be instructed in the appropriate technique, although emphasis is not on examination techniques. PreferredName:Woman SemanticType:[popg] PreferredName:desires SemanticType:[menp] PreferredName:To SemanticType:[qlco] PreferredName:Performed SemanticType:[ftcn] PreferredName:Self awareness SemanticType:[menp] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Part Dosing Unit SemanticType:[qnco] PreferredName:strategy SemanticType:[menp] PreferredName:Appropriate SemanticType:[qlco] PreferredName:Techniques SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Examination by method SemanticType:[diap] POS:NNS POS:WP POS:VBP POS:TO POS:VB POS:JJ POS:IN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:NN POS:MD POS:VB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:, POS:IN POS:NN POS:VBZ POS:RB POS:IN POS:NN POS:NNS POS:. 
[sentNum: 166]<Annotation Id="13101" Type="Sentence" StartNode="16330" EndNode="16410">Women should report any changes in their breasts to their health care providers. PreferredName:Woman SemanticType:[popg] PreferredName:Reporting SemanticType:[hlca] PreferredName:Breast changes SemanticType:[fndg] PreferredName:Health Personnel SemanticType:[prog] POS:NNS POS:MD POS:VB POS:DT POS:NNS POS:IN POS:PRP$ POS:NNS POS:TO POS:PRP$ POS:NN POS:NN POS:NNS POS:. 
[sentNum: 167]<Annotation Id="13102" Type="Sentence" StartNode="16411" EndNode="16717">Although this patient education strategy has not been studied to date, breast awareness may be of particular importance as part of a screening strategy because some women may falsely assume that negative mammography or clinical breast examination results definitively exclude the presence of breast cancer. PreferredName:Respiratory Therapist, Registered - Patient Education SemanticType:[prog] PreferredName:strategy SemanticType:[menp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Study Start Date SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Awareness SemanticType:[menp] PreferredName:Exist SemanticType:[cnce] PreferredName:Part of SemanticType:[spco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Woman SemanticType:[popg] PreferredName:Negative SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Result SemanticType:[ftcn] PreferredName:Exclusion SemanticType:[acty] PreferredName:Presence SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:IN POS:DT POS:NN POS:NN POS:NN POS:VBZ POS:RB POS:VBN POS:VBN POS:TO POS:NN POS:, POS:NN POS:NN POS:MD POS:VB POS:IN POS:JJ POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:NN POS:IN POS:DT POS:NNS POS:MD POS:RB POS:VB POS:IN POS:JJ POS:NN POS:CC POS:JJ POS:NN POS:NN POS:NNS POS:RB POS:VBP POS:DT POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 168]<Annotation Id="13103" Type="Sentence" StartNode="16718" EndNode="16923">New cases of cancer can arise during screening intervals, and breast self-awareness may prompt women not to delay in reporting breast changes based on false reassurance of recent negative screening result. PreferredName:New SemanticType:[tmco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Interval SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Prompting SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Deferred SemanticType:[tmco] PreferredName:Reporting SemanticType:[hlca] PreferredName:Breast changes SemanticType:[fndg] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] PreferredName:Group reassurance SemanticType:[topp] PreferredName:Recent SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:JJ POS:NNS POS:IN POS:NN POS:MD POS:VB POS:IN POS:NN POS:NNS POS:, POS:CC POS:NN POS:NN POS:MD POS:VB POS:NNS POS:RB POS:TO POS:VB POS:IN POS:VBG POS:NN POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:JJ POS:NN POS:NN POS:. 
[sentNum: 169]<Annotation Id="13104" Type="Sentence" StartNode="16924" EndNode="17097">Breast self-awareness aims to capture the importance of self-detection and prompt evaluation of symptoms because it relates to overall breast cancer morbidity and mortality. PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Aim (idea) SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:subscriber - self SemanticType:[inpr] PreferredName:Detection SemanticType:[topp] PreferredName:Prompting SemanticType:[ftcn] PreferredName:Symptom Evaluation SemanticType:[hlca] PreferredName:Relate - vinyl resin SemanticType:[orch] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] POS:NN POS:NN POS:VBZ POS:TO POS:VB POS:DT POS:NN POS:IN POS:NN POS:CC POS:VB POS:NN POS:IN POS:NNS POS:IN POS:PRP POS:VBZ POS:TO POS:JJ POS:NN POS:NN POS:NN POS:CC POS:NN POS:. 
[sentNum: 170]<Annotation Id="13105" Type="Sentence" StartNode="17098" EndNode="17174">However, the effect of breast self-awareness education has not been studied.PreferredName:Effect SemanticType:[qlco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Educational Status SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Study SemanticType:[resa] POS:RB POS:, POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:VBZ POS:RB POS:VBN POS:VBN POS:. 
[sentNum: 171]<Annotation Id="13106" Type="Sentence" StartNode="17176" EndNode="17403">The United States Preventive Services Task Force has recommended against teaching breast self-examination based on a lack of evidence to show benefit and potential harm resulting from evaluation of false-positive findings (23). PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Lacking SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Show SemanticType:[inpr] PreferredName:Benefits SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] PreferredName:Device Evaluation Result SemanticType:[idcn] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Arabic numeral 23 SemanticType:[qnco] POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:VBZ POS:VBN POS:IN POS:VBG POS:NN POS:NN POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:TO POS:VB POS:NN POS:CC POS:JJ POS:NN POS:VBG POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 172]<Annotation Id="13107" Type="Sentence" StartNode="17404" EndNode="17629">A prospective study of 604 patients with breast cancer revealed that only 7.6% of the 448 women who practiced regular breast self-examination had detected their own cancer, and those who did showed no survival advantage (31). PreferredName:Prospective Studies SemanticType:[resa] PreferredName:Patients SemanticType:[podg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Revealed SemanticType:[qlco] PreferredName:Singular SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Regular SemanticType:[qlco] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Detection SemanticType:[topp] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Show SemanticType:[inpr] PreferredName:Continuance of life SemanticType:[acty] PreferredName:Arabic numeral 31 SemanticType:[inpr] POS:DT POS:JJ POS:NN POS:IN POS:CD POS:NNS POS:IN POS:NN POS:NN POS:VBD POS:IN POS:RB POS:CD POS:. POS:CD POS:NN POS:IN POS:DT POS:CD POS:NNS POS:WP POS:VBD POS:JJ POS:NN POS:NN POS:VBD POS:VBN POS:PRP$ POS:JJ POS:NN POS:, POS:CC POS:DT POS:WP POS:VBD POS:VBD POS:DT POS:NN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 173]<Annotation Id="13108" Type="Sentence" StartNode="17630" EndNode="17989">The Shanghai breast self-examination trial of 266,000 women aged 39–72 years randomized to receive either breast self-examination instruction plus follow-up or no information on breast cancer screening reported essentially no difference in breast cancer-related deaths between the two groups (135 versus 131, respectively) after 10–11 years of follow-up (32). PreferredName:subscriber - self SemanticType:[inpr] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Randomization SemanticType:[resa] PreferredName:To SemanticType:[qlco] PreferredName:Receive SemanticType:[qlco] PreferredName:Breast self-examination technique education SemanticType:[hlca] PreferredName:In addition to SemanticType:[qlco] PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:No Information Available SemanticType:[qlco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Reporting SemanticType:[hlca] PreferredName:No status change SemanticType:[fndg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Death Relationship SemanticType:[fndg] PreferredName:Two SemanticType:[qnco] PreferredName:Groups SemanticType:[idcn] PreferredName:Status post SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Follow-Up Report SemanticType:[inpr] POS:DT POS:NNP POS:NN POS:NN POS:NN POS:IN POS:CD POS:, POS:CD POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:VBN POS:TO POS:VB POS:DT POS:NN POS:NN POS:NN POS:CC POS:NN POS:CC POS:DT POS:NN POS:IN POS:NN POS:NN POS:NN POS:VBD POS:RB POS:DT POS:NN POS:IN POS:NN POS:JJ POS:NNS POS:IN POS:DT POS:CD POS:NNS POS:( POS:CD POS:IN POS:CD POS:, POS:RB POS:) POS:IN POS:CD POS:JJ POS:CD POS:NNS POS:IN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 174]<Annotation Id="13109" Type="Sentence" StartNode="17990" EndNode="18096">However, women in the instruction group were more likely to undergo breast biopsy for benign lesions (32).PreferredName:Women's Groups SemanticType:[popg] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:More SemanticType:[ftcn] PreferredName:Probably SemanticType:[idcn] PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:Benign SemanticType:[qlco] PreferredName:Lesion SemanticType:[fndg] POS:RB POS:, POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:VBD POS:RBR POS:JJ POS:TO POS:VB POS:NN POS:NN POS:IN POS:JJ POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 175]<Annotation Id="13110" Type="Sentence" StartNode="18098" EndNode="18297">A Cochrane systematic review published in 2003 included the Shanghai breast trial (32) and another large population-based study from Russia that compared breast self-examination with no intervention. PreferredName:Review, Systematic SemanticType:[inpr] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Large SemanticType:[qnco] PreferredName:Population Based Study SemanticType:[resa] PreferredName:Russia SemanticType:[geoa] PreferredName:Comparison SemanticType:[acty] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Intervention regimes SemanticType:[hlca] POS:DT POS:NNP POS:JJ POS:NN POS:VBN POS:IN POS:CD POS:VBD POS:DT POS:NNP POS:NN POS:NN POS:( POS:CD POS:) POS:CC POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:NNP POS:WDT POS:VBD POS:NN POS:NN POS:IN POS:DT POS:NN POS:. 
[sentNum: 176]<Annotation Id="13111" Type="Sentence" StartNode="18298" EndNode="18439">In both trials, almost twice as many biopsies with benign results were performed in the screening group compared with the control group (33). PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Twice (Numerical Qualifier) SemanticType:[qnco] PreferredName:Biopsy SemanticType:[diap] PreferredName:Benign SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Performed SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Groups SemanticType:[idcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Control Groups SemanticType:[grup] POS:IN POS:DT POS:NNS POS:, POS:RB POS:RB POS:IN POS:JJ POS:NNS POS:IN POS:JJ POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:NN POS:NN POS:VBN POS:IN POS:DT POS:NN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 177]<Annotation Id="13112" Type="Sentence" StartNode="18440" EndNode="18653">The Canadian Task Force on Preventive Health Care also recommended against teaching breast self-examination based on fair evidence that breast self-examination had no benefit and good evidence that it was harmful. PreferredName:CANADIAN SemanticType:[fndg] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:preventive health care SemanticType:[topp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Fair (qualifier) SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Breast Self-Examination SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] PreferredName:Good SemanticType:[qlco] PreferredName:Evidence of SemanticType:[ftcn] POS:DT POS:JJ POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:NNP POS:RB POS:VBD POS:IN POS:VBG POS:NN POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:VBD POS:DT POS:NN POS:CC POS:JJ POS:NN POS:IN POS:PRP POS:VBD POS:JJ POS:. 
[sentNum: 178]<Annotation Id="13113" Type="Sentence" StartNode="18654" EndNode="18804">Their review cited additional evidence that patients experience increased worry, anxiety, and depression associated with breast self-examination (34).PreferredName:Act Class - review SemanticType:[idcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Patients SemanticType:[podg] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Increase SemanticType:[ftcn] PreferredName:Worried SemanticType:[fndg] PreferredName:Anxiety SemanticType:[menp] PreferredName:Mental Depression SemanticType:[mobd] PreferredName:Associated with SemanticType:[qlco] PreferredName:Breast Self-Examination SemanticType:[diap] POS:PRP$ POS:NN POS:VBD POS:JJ POS:NN POS:IN POS:NNS POS:VBP POS:JJ POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:VBN POS:IN POS:NN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 179]<Annotation Id="13114" Type="Sentence" StartNode="18806" EndNode="19048">Because other screening methods (mammography and clinical breast examination) can have false-negative results and cases of breast cancer can occur in unscreened women, there are clearly situations in which women will detect cancer themselves. PreferredName:Screening procedure SemanticType:[hlca] PreferredName:Mammography SemanticType:[diap] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Occurrence SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Primary malignant neoplasm SemanticType:[neop] POS:IN POS:JJ POS:NN POS:NNS POS:( POS:NN POS:CC POS:JJ POS:NN POS:NN POS:) POS:MD POS:VB POS:JJ POS:NNS POS:CC POS:NNS POS:IN POS:NN POS:NN POS:MD POS:VB POS:IN POS:JJ POS:NNS POS:, POS:EX POS:VBP POS:RB POS:NNS POS:IN POS:WDT POS:NNS POS:MD POS:VB POS:NN POS:PRP POS:. 
[sentNum: 180]<Annotation Id="13115" Type="Sentence" StartNode="19049" EndNode="19284">As such, the College, the American Cancer Society, and the National Comprehensive Cancer Network endorse educating women aged 20 years and older regarding breast self-awareness, as a means to play a role in earlier detection (Table 2).PreferredName:College SemanticType:[mnob] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Means SemanticType:[cnce] PreferredName:Does play SemanticType:[fndg] PreferredName:Social Role SemanticType:[socb] PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:Table - furniture SemanticType:[mnob] POS:IN POS:JJ POS:, POS:DT POS:NNP POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:VBP POS:VBG POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:VBG POS:NN POS:NN POS:, POS:IN POS:DT POS:NNS POS:TO POS:VB POS:DT POS:NN POS:IN POS:JJR POS:NN POS:( POS:CD POS:CD POS:) POS:. 
[sentNum: 181]<Annotation Id="13116" Type="Sentence" StartNode="19290" EndNode="19396">Is clinical (ie, health care provider performed) breast examination effective for breast cancer screening? PreferredName:Clinical SemanticType:[qlco] PreferredName:Health Personnel SemanticType:[prog] PreferredName:Performed SemanticType:[ftcn] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Effective SemanticType:[qlco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:VBZ POS:JJ POS:( POS:NNP POS:, POS:NN POS:NN POS:NN POS:VBN POS:) POS:NN POS:NN POS:JJ POS:IN POS:NN POS:NN POS:NN POS:. 
[sentNum: 182]<Annotation Id="13117" Type="Sentence" StartNode="19397" EndNode="19442">If so, how frequently should it be performed?PreferredName:Somalia SemanticType:[geoa] PreferredName:Frequent SemanticType:[tmco] PreferredName:Performed SemanticType:[ftcn] POS:IN POS:RB POS:, POS:WRB POS:RB POS:MD POS:PRP POS:VB POS:VBN POS:. 
[sentNum: 183]<Annotation Id="13118" Type="Sentence" StartNode="19444" EndNode="19776">A study using data from the National Breast and Cervical Cancer Early Detection Program, where 752,081 clinical breast examinations were performed in the community setting in women aged 40 years and older, concluded that clinical breast examination alone has a sensitivity for cancer detection of 58.8%, with a specificity of 93.4%. PreferredName:Study SemanticType:[resa] PreferredName:Use of SemanticType:[ftcn] PreferredName:Data SemanticType:[idcn] PreferredName:National citizen SemanticType:[inpr] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:early detection of cervical cancer SemanticType:[topp] PreferredName:Program SemanticType:[phsu] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Performed SemanticType:[ftcn] PreferredName:Community SemanticType:[geoa] PreferredName:contextual factors SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:alone - group size SemanticType:[grpa] PreferredName:Statistical sensitivity SemanticType:[qnco] PreferredName:Cancer Detection SemanticType:[hlca] PreferredName:With - dosing instruction fragment SemanticType:[inpr] PreferredName:Specificity SemanticType:[qnco] POS:DT POS:NN POS:VBG POS:NNS POS:IN POS:DT POS:NNP POS:NNP POS:CC POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:, POS:WRB POS:CD POS:, POS:CD POS:JJ POS:NN POS:NNS POS:VBD POS:VBN POS:IN POS:DT POS:NN POS:VBG POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:, POS:VBD POS:IN POS:JJ POS:NN POS:NN POS:RB POS:VBZ POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:CD POS:. POS:CD POS:NN POS:, POS:IN POS:DT POS:NN POS:IN POS:CD POS:. POS:CD POS:NN POS:. 
[sentNum: 184]<Annotation Id="13119" Type="Sentence" StartNode="19777" EndNode="19881">In this population, five cases of cancer were detected per 1,000 clinical breast examinations performed. PreferredName:geographic population SemanticType:[qnco] PreferredName:Five SemanticType:[qnco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Performed SemanticType:[ftcn] POS:IN POS:DT POS:NN POS:, POS:CD POS:NNS POS:IN POS:NN POS:VBD POS:VBN POS:IN POS:CD POS:, POS:CD POS:JJ POS:NN POS:NNS POS:VBN POS:. 
[sentNum: 185]<Annotation Id="13120" Type="Sentence" StartNode="19882" EndNode="20025">When the clinical breast examination finding was abnormal and the mammogram was normal, 7.4 cases of cancer were detected per 1,000 screenings. PreferredName:Physical findings SemanticType:[fndg] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Abnormal Reference Range SemanticType:[inpr] PreferredName:Mammography SemanticType:[diap] PreferredName:Normal SemanticType:[qlco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Screening procedure SemanticType:[hlca] POS:WRB POS:DT POS:JJ POS:NN POS:NN POS:NN POS:VBD POS:JJ POS:CC POS:DT POS:NN POS:VBD POS:JJ POS:, POS:CD POS:. POS:CD POS:NNS POS:IN POS:NN POS:VBD POS:VBN POS:IN POS:CD POS:, POS:CD POS:NNS POS:. 
[sentNum: 186]<Annotation Id="13121" Type="Sentence" StartNode="20026" EndNode="20138">The authors concluded that the addition of clinical breast examination “modestly improved” early detection (35).PreferredName:Journalist SemanticType:[prog] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Clinical SemanticType:[qlco] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Improved SemanticType:[qlco] PreferredName:Early Diagnosis SemanticType:[diap] POS:DT POS:NNS POS:VBD POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NN POS:NNS POS:RB POS:VBD POS:NN POS:JJ POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 187]<Annotation Id="13122" Type="Sentence" StartNode="20140" EndNode="20271">Multiple reviews have supported the combination of clinical breast examination and mammography for breast cancer screening (36–41). PreferredName:Numerous SemanticType:[qnco] PreferredName:Review [Publication Type] SemanticType:[inpr] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Combined SemanticType:[qlco] PreferredName:Clinical SemanticType:[qlco] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:JJ POS:NNS POS:VBP POS:VBN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:NN POS:CC POS:NN POS:IN POS:NN POS:NN POS:NN POS:( POS:$ POS:CD POS:CD POS:) POS:. 
[sentNum: 188]<Annotation Id="13123" Type="Sentence" StartNode="20272" EndNode="20453">A recent study demonstrated improved sensitivity for breast cancer detection (94.6% versus 88.6%) when comparing mammography plus clinical breast examination with mammography alone. PreferredName:Recent SemanticType:[tmco] PreferredName:Study SemanticType:[resa] PreferredName:Improved SemanticType:[qlco] PreferredName:Statistical sensitivity SemanticType:[qnco] PreferredName:Breast Cancer Detection Research SemanticType:[hlca] PreferredName:Comparison SemanticType:[acty] PreferredName:Mammography SemanticType:[diap] PreferredName:In addition to SemanticType:[qlco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Mammography SemanticType:[diap] PreferredName:alone - group size SemanticType:[grpa] POS:DT POS:JJ POS:NN POS:VBD POS:VBN POS:NN POS:IN POS:NN POS:NN POS:NN POS:( POS:CD POS:. POS:CD POS:NN POS:IN POS:CD POS:. POS:CD POS:NN POS:) POS:WRB POS:VBG POS:NN POS:CC POS:JJ POS:NN POS:NN POS:IN POS:NN POS:RB POS:. 
[sentNum: 189]<Annotation Id="13124" Type="Sentence" StartNode="20454" EndNode="20621">However, the false-positive rate was also higher in the group receiving clinical breast examination compared with the mammography-alone group (12.4% versus 7.4%) (41). PreferredName:False Discovery Rate SemanticType:[qnco] PreferredName:High SemanticType:[qlco] PreferredName:Groups SemanticType:[idcn] PreferredName:Receive SemanticType:[qlco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Comparison SemanticType:[acty] PreferredName:Mammography SemanticType:[diap] PreferredName:Single Group Study SemanticType:[resa] POS:RB POS:, POS:DT POS:JJ POS:NN POS:VBD POS:RB POS:JJR POS:IN POS:DT POS:NN POS:VBG POS:JJ POS:NN POS:NN POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:( POS:CD POS:. POS:CD POS:NN POS:FW POS:CD POS:. POS:CD POS:NN POS:) POS:( POS:CD POS:) POS:. 
[sentNum: 190]<Annotation Id="13125" Type="Sentence" StartNode="20622" EndNode="20845">Based on available evidence, the College, the American Cancer Society, and the National Comprehensive Cancer Network recommend that clinical breast examination should be performed annually for women aged 40 years and older. PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:College SemanticType:[mnob] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Performed SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] POS:VBN POS:IN POS:JJ POS:NN POS:, POS:DT POS:NNP POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:VBP POS:IN POS:JJ POS:NN POS:NN POS:MD POS:VB POS:VBN POS:RB POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:. 
[sentNum: 191]<Annotation Id="13126" Type="Sentence" StartNode="20846" EndNode="21168">Although the value of screening clinical breast examination for women with a low prevalence of breast cancer (ie, women aged 20–39 years) is not clear, the College, the American Cancer Society, and the National Comprehensive Cancer Network continue to recommend clinical breast examination for these women every 1–3 years.PreferredName:Numerical value SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Clinical SemanticType:[qlco] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Low Prevalence SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Clear SemanticType:[qlco] PreferredName:College SemanticType:[mnob] PreferredName:American Cancer Society SemanticType:[pros] PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:Continuous SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:1+ Score SemanticType:[qnco] PreferredName:year SemanticType:[tmco] POS:IN POS:DT POS:NN POS:IN POS:VBG POS:JJ POS:NN POS:NN POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:( POS:NN POS:, POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:) POS:VBZ POS:RB POS:JJ POS:, POS:DT POS:NNP POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:VBP POS:TO POS:VB POS:JJ POS:NN POS:NN POS:IN POS:DT POS:NNS POS:DT POS:CD POS:CD POS:CD POS:NNS POS:. 
[sentNum: 192]<Annotation Id="13127" Type="Sentence" StartNode="21174" EndNode="21256">When should mammography begin, and how frequently should mammography be performed?PreferredName:Mammography SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Frequent SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Performed SemanticType:[ftcn] POS:WRB POS:MD POS:NN POS:VB POS:, POS:CC POS:WRB POS:RB POS:MD POS:NNP POS:VB POS:VBN POS:. 
[sentNum: 193]<Annotation Id="13128" Type="Sentence" StartNode="21258" EndNode="21502">Based on the incidence of breast cancer, the sojourn time for breast cancer growth, and the potential for reduction in breast cancer mortality, the College recommends that women aged 40 years and older be offered screening mammography annually. PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:growth aspects SemanticType:[phsf] PreferredName:Potential SemanticType:[qlco] PreferredName:Reduction mammaplasty SemanticType:[topp] PreferredName:Cancer Death Rate SemanticType:[qnco] PreferredName:College SemanticType:[mnob] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Offered SemanticType:[fndg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NN POS:, POS:CC POS:DT POS:NN POS:IN POS:NN POS:IN POS:NN POS:NN POS:NN POS:, POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:VB POS:VBN POS:VBG POS:RB POS:RB POS:. 
[sentNum: 194]<Annotation Id="13129" Type="Sentence" StartNode="21503" EndNode="21673">However, as with any screening test, women should be educated on the predictive value of the test and the potential for false-positive results and false-negative results. PreferredName:Screening Tests SemanticType:[hlca] PreferredName:Woman SemanticType:[popg] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Predictive Value of Tests SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] POS:RB POS:, POS:IN POS:IN POS:DT POS:NN POS:NN POS:, POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NN POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 195]<Annotation Id="13130" Type="Sentence" StartNode="21674" EndNode="21802">Women should be informed of the potential for additional imaging or biopsies that may be recommended based on screening results. PreferredName:Woman SemanticType:[popg] PreferredName:Informed SemanticType:[qlco] PreferredName:Potential SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Biopsy SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:CC POS:NNS POS:WDT POS:MD POS:VB POS:VBN POS:VBN POS:IN POS:VBG POS:NNS POS:. 
[sentNum: 196]<Annotation Id="13131" Type="Sentence" StartNode="21803" EndNode="21923">The physician should work with the patient to determine the best screening strategy based on individual risk and values. PreferredName:Physicians SemanticType:[prog] PreferredName:Work SemanticType:[ocac] PreferredName:Patients SemanticType:[podg] PreferredName:best (quality) SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Individual SemanticType:[humn] PreferredName:Risk SemanticType:[qlco] PreferredName:Values SemanticType:[qlco] POS:DT POS:NN POS:MD POS:VB POS:IN POS:DT POS:NN POS:TO POS:VB POS:DT POS:JJS POS:NN POS:NN POS:VBN POS:IN POS:JJ POS:NN POS:CC POS:NNS POS:. 
[sentNum: 197]<Annotation Id="13132" Type="Sentence" StartNode="21924" EndNode="22007">In some women, biennial screening may be a more appropriate or acceptable strategy. PreferredName:Woman SemanticType:[popg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:More SemanticType:[ftcn] PreferredName:Appropriate SemanticType:[qlco] PreferredName:Acceptable SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] POS:IN POS:DT POS:NNS POS:, POS:NN POS:NN POS:MD POS:VB POS:DT POS:RBR POS:JJ POS:CC POS:JJ POS:NN POS:. 
[sentNum: 198]<Annotation Id="13133" Type="Sentence" StartNode="22008" EndNode="22286">Some average-risk women may prefer biennial screening, which maintains most of the benefits of screening while minimizing both the frequency of screening and the potential for additional testing, whereas other women prefer annual screening because it maximizes cancer detection.PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Maintenance SemanticType:[acty] PreferredName:Most SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Both SemanticType:[qlco] PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Potential SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Testing SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:annual screening SemanticType:[diap] PreferredName:Cancer Detection SemanticType:[hlca] POS:DT POS:JJ POS:NNS POS:MD POS:VB POS:JJ POS:NN POS:, POS:WDT POS:VBZ POS:JJS POS:IN POS:DT POS:NNS POS:IN POS:NN POS:IN POS:VBG POS:PDT POS:DT POS:NN POS:IN POS:NN POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NN POS:, POS:IN POS:JJ POS:NNS POS:VBP POS:JJ POS:NN POS:IN POS:PRP POS:VBZ POS:NN POS:NN POS:. 
[sentNum: 199]<Annotation Id="13134" Type="Sentence" StartNode="22288" EndNode="22399">Various groups have offered recommendations on the timing of initiation and frequency of mammography screening. PreferredName:Various patch test substance SemanticType:[irda] PreferredName:Groups SemanticType:[idcn] PreferredName:Offered SemanticType:[fndg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Timing SemanticType:[tmco] PreferredName:Initiation SemanticType:[ftcn] PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] POS:JJ POS:NNS POS:VBP POS:VBN POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:CC POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 200]<Annotation Id="13135" Type="Sentence" StartNode="22400" EndNode="22784">Each group places different values on competing considerations, such as published evidence, cost-effectiveness, efficiency, accuracy, adverse consequences, specificity, sensitivity, false-positive results, false-negative results, positive predictive value, patient adherence, availability of health care resources, conflicting health care needs, and opinions of experts and advocates. PreferredName:Groups SemanticType:[idcn] PreferredName:Place SemanticType:[spco] PreferredName:Change values SemanticType:[inpr] PreferredName:consideration SemanticType:[fndg] PreferredName:Scientific Publication SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Cost Effectiveness SemanticType:[qnco] PreferredName:Efficiency SemanticType:[qnco] PreferredName:Accurate (qualifier) SemanticType:[qlco] PreferredName:Consequence of SemanticType:[ftcn] PreferredName:Specificity SemanticType:[qnco] PreferredName:Statistical sensitivity SemanticType:[qnco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] PreferredName:Positive Predictive Value of Diagnostic Test SemanticType:[qnco] PreferredName:Compliance behavior SemanticType:[inbe] PreferredName:Availability of SemanticType:[ftcn] PreferredName:health care resources SemanticType:[qnco] PreferredName:Conflict (Psychology) SemanticType:[inbe] PreferredName:Health Care SemanticType:[hlca] PreferredName:Needs SemanticType:[qlco] PreferredName:Expert Opinion SemanticType:[cnce] PreferredName:Advocate (person) SemanticType:[ocdi] POS:DT POS:NN POS:VBZ POS:JJ POS:NNS POS:IN POS:VBG POS:NNS POS:, POS:JJ POS:IN POS:VBN POS:NN POS:, POS:NNS POS:, POS:NN POS:, POS:NN POS:, POS:JJ POS:NNS POS:, POS:NN POS:, POS:NN POS:, POS:JJ POS:NNS POS:, POS:JJ POS:NNS POS:, POS:JJ POS:JJ POS:NN POS:, POS:JJ POS:NN POS:, POS:NN POS:IN POS:NN POS:NN POS:NNS POS:, POS:VBG POS:NN POS:NN POS:NNS POS:, POS:CC POS:NNS POS:IN POS:NNS POS:CC POS:NNS POS:. 
[sentNum: 201]<Annotation Id="13136" Type="Sentence" StartNode="22785" EndNode="22842">A summary of the recommendations can be found in Table 2.PreferredName:Summary (document) SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Present SemanticType:[qnco] PreferredName:Table - furniture SemanticType:[mnob] POS:DT POS:NN POS:IN POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:NN POS:CD POS:. 
[sentNum: 202]<Annotation Id="13137" Type="Sentence" StartNode="22844" EndNode="22992">The American Cancer Society and the National Comprehensive Cancer Network recommend annual screening mammography beginning at age 40 years (42, 43). PreferredName:American Cancer Society SemanticType:[pros] PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:Recommendation SemanticType:[idcn] PreferredName:annual screening SemanticType:[diap] PreferredName:Mammography SemanticType:[diap] PreferredName:Beginning SemanticType:[tmco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] POS:DT POS:NNP POS:NNP POS:NNP POS:CC POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:VBP POS:JJ POS:NN POS:RB POS:VBG POS:IN POS:NN POS:CD POS:NNS POS:( POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 203]<Annotation Id="13138" Type="Sentence" StartNode="22993" EndNode="23149">In contrast, the United States Preventive Services Task Force recently changed their guidelines to recommend biennial mammography in women aged 50–74 years. PreferredName:Contrast SemanticType:[qlco] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Recent SemanticType:[tmco] PreferredName:Changing SemanticType:[ftcn] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] POS:IN POS:NN POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:RB POS:VBD POS:PRP$ POS:NNS POS:TO POS:VB POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNP POS:CD POS:NNS POS:. 
[sentNum: 204]<Annotation Id="13139" Type="Sentence" StartNode="23150" EndNode="23387">Although routine screening in women aged 40–49 years was not recommended, the Task Force advised that screening in women younger than 50 years should be individualized based on “patient values regarding specific benefits and harms” (23).PreferredName:Routine SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Individualized SemanticType:[qlco] PreferredName:Patient Base SemanticType:[qnco] PreferredName:Values SemanticType:[qlco] PreferredName:Specific qualifier value SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Arabic numeral 23 SemanticType:[qnco] POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:VBD POS:RB POS:VBN POS:, POS:DT POS:NNP POS:NNP POS:VBD POS:IN POS:NN POS:IN POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:MD POS:VB POS:VBN POS:VBN POS:IN POS:JJ POS:JJ POS:NNS POS:VBG POS:JJ POS:NNS POS:CC POS:NNP POS:NNP POS:( POS:CD POS:) POS:. 
[sentNum: 205]<Annotation Id="13140" Type="Sentence" StartNode="23389" EndNode="23725">The American Cancer Society, the National Comprehensive Cancer Network, and the United States Preventive Services Task Force agree that screening mammography reduces breast cancer-related mortality in women aged 40 years and older based on meta-analyses of available randomized controlled trials on mammographic screening (see Table 3). PreferredName:American Cancer Society SemanticType:[pros] PreferredName:National Comprehensive Cancer Network SemanticType:[hcro] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Agree SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Randomized Controlled Trials as Topic SemanticType:[inpr, resa] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Vision SemanticType:[orgf] PreferredName:Table - furniture SemanticType:[mnob] POS:DT POS:NNP POS:NNP POS:NNP POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:, POS:CC POS:DT POS:NNP POS:NNPS POS:NNP POS:NNP POS:NNP POS:NNP POS:VBP POS:IN POS:NN POS:NN POS:VBZ POS:NN POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:VBN POS:IN POS:NNS POS:IN POS:JJ POS:JJ POS:JJ POS:NNS POS:IN POS:JJ POS:NN POS:( POS:VB POS:NNP POS:CD POS:) POS:. 
[sentNum: 206]<Annotation Id="13141" Type="Sentence" StartNode="23726" EndNode="24098">However, the United States Preventive Services Task Force arrived at a different conclusion regarding routine screening for women aged 40–49 years by placing greater weight on the lower prevalence of disease in this population, which reduces the positive predictive value of mammography and increases the number needed to screen to prevent one breast cancer-related death. PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Arrival - action SemanticType:[acty] PreferredName:Different SemanticType:[qlco] PreferredName:Conclusion SemanticType:[idcn] PreferredName:Routine SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Place SemanticType:[spco] PreferredName:Greater SemanticType:[qnco] PreferredName:Weight SemanticType:[qnco] PreferredName:Upon - dosing instruction fragment SemanticType:[ftcn] PreferredName:Lower - spatial qualifier SemanticType:[spco] PreferredName:disorder prevalence SemanticType:[qnco] PreferredName:geographic population SemanticType:[qnco] PreferredName:Positive Predictive Value of Diagnostic Test SemanticType:[qnco] PreferredName:Mammography SemanticType:[diap] PreferredName:Increase SemanticType:[ftcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:Needs SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:PREVENT (product) SemanticType:[phsu] PreferredName:One SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Cessation of life SemanticType:[orgf] POS:RB POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:NNP POS:VBD POS:IN POS:DT POS:JJ POS:NN POS:VBG POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNP POS:CD POS:NNS POS:IN POS:VBG POS:JJR POS:NN POS:IN POS:DT POS:JJR POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:, POS:WDT POS:VBZ POS:DT POS:JJ POS:JJ POS:NN POS:IN POS:NN POS:CC POS:VBZ POS:DT POS:NN POS:VBN POS:TO POS:VB POS:TO POS:VB POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 207]<Annotation Id="13142" Type="Sentence" StartNode="24099" EndNode="24410">In addition, the United States Preventive Services Task Force argues that all women who participate in breast cancer screening may potentially experience a false-positive mammogram (as high as 49% of women after 10 years of screening), with resultant additional imaging, biopsies, and psychologic distress (44). PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Woman SemanticType:[popg] PreferredName:Present SemanticType:[qnco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Practice Experience SemanticType:[menp] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:High SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Status post SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Biopsy SemanticType:[diap] PreferredName:psychological distress SemanticType:[mobd] POS:IN POS:NN POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:VBZ POS:IN POS:DT POS:NNS POS:WP POS:VBP POS:IN POS:NN POS:NN POS:NN POS:MD POS:RB POS:VB POS:DT POS:JJ POS:NN POS:( POS:RB POS:JJ POS:IN POS:CD POS:NN POS:IN POS:NNS POS:IN POS:CD POS:NNS POS:IN POS:NN POS:) POS:, POS:IN POS:JJ POS:JJ POS:NN POS:, POS:NNS POS:, POS:CC POS:JJ POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 208]<Annotation Id="13143" Type="Sentence" StartNode="24411" EndNode="24618">The burden of these additional tests may be perceived as greater on women aged 40–49 years because they are less likely to experience breast cancer and, therefore, less likely to benefit from screening (23).PreferredName:Burden SemanticType:[idcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Perception SemanticType:[menp] PreferredName:Greater SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Less Than SemanticType:[inpr] PreferredName:Probably SemanticType:[idcn] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Less Than SemanticType:[inpr] PreferredName:Probably SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Arabic numeral 23 SemanticType:[qnco] POS:DT POS:NN POS:IN POS:DT POS:JJ POS:NNS POS:MD POS:VB POS:VBN POS:RB POS:JJR POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:IN POS:PRP POS:VBP POS:RBR POS:JJ POS:TO POS:VB POS:NN POS:NN POS:CC POS:, POS:RB POS:, POS:RBR POS:JJ POS:TO POS:VB POS:IN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 209]<Annotation Id="13144" Type="Sentence" StartNode="24620" EndNode="24965">In response to this argument, experts who support routine screening for women in their 40s note that although the incidence of cancer is less in the 40–49 year age group than in all women older than 50 years, the incidence of cancer in women in their 50s (1 in 38, or 2.60%) is not much higher than in women in their 40s (1 in 69, or 1.44%) (2). PreferredName:Present SemanticType:[qnco] PreferredName:Disease Response SemanticType:[fndg] PreferredName:Programming Parameter SemanticType:[cnce] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Routine SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider} SemanticType:[clna] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Less Than SemanticType:[inpr] PreferredName:/40 SemanticType:[tmco] PreferredName:per year SemanticType:[tmco] PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Woman SemanticType:[popg] PreferredName:Old SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Present SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:1+ Score SemanticType:[qnco] PreferredName:2+ Score SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:High SemanticType:[qlco] PreferredName:Present SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:1+ Score SemanticType:[qnco] PreferredName:2+ Score SemanticType:[qnco] POS:IN POS:NN POS:TO POS:DT POS:NN POS:, POS:NNS POS:WP POS:VBP POS:JJ POS:NN POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:VBP POS:IN POS:IN POS:DT POS:NN POS:IN POS:NN POS:VBZ POS:RBR POS:IN POS:DT POS:CD POS:NNS POS:CD POS:NN POS:NN POS:NN POS:IN POS:IN POS:DT POS:NNS POS:JJR POS:IN POS:CD POS:NNS POS:, POS:DT POS:NN POS:IN POS:NN POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:( POS:CD POS:IN POS:CD POS:, POS:CC POS:CD POS:. POS:CD POS:NN POS:) POS:VBZ POS:RB POS:RB POS:JJR POS:IN POS:IN POS:NNS POS:IN POS:PRP$ POS:CD POS:NNS POS:( POS:CD POS:IN POS:CD POS:, POS:CC POS:CD POS:. POS:CD POS:NN POS:) POS:( POS:CD POS:) POS:. 
[sentNum: 210]<Annotation Id="13145" Type="Sentence" StartNode="24966" EndNode="25207">In addition, women who undergo routine screening mammography in their 40s have comparable mortality reduction compared with women who undergo routine mammography screening in their 50s (16% reduction versus 15% reduction, respectively) (17). PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Routine SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:/40 SemanticType:[tmco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Comparison SemanticType:[acty] PreferredName:Woman SemanticType:[popg] PreferredName:Routine SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Reduction - action SemanticType:[topp] POS:IN POS:NN POS:, POS:NNS POS:WP POS:VBP POS:JJ POS:NN POS:NN POS:IN POS:PRP$ POS:CD POS:NNS POS:VBP POS:JJ POS:NN POS:NN POS:VBN POS:IN POS:NNS POS:WP POS:VBP POS:JJ POS:NN POS:NN POS:IN POS:PRP$ POS:CD POS:NNS POS:( POS:CD POS:NN POS:NN POS:IN POS:CD POS:NN POS:NN POS:, POS:RB POS:) POS:( POS:CD POS:) POS:. 
[sentNum: 211]<Annotation Id="13146" Type="Sentence" StartNode="25208" EndNode="25359">This is of particular importance because each year in the United States breast cancer is diagnosed in approximately 50,000 women younger than 50 years.PreferredName:Each (qualifier value) SemanticType:[qnco] PreferredName:per year SemanticType:[tmco] PreferredName:United States SemanticType:[geoa] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Approximate SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Young SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:DT POS:VBZ POS:IN POS:JJ POS:NN POS:IN POS:DT POS:NN POS:IN POS:DT POS:NNP POS:NNPS POS:NN POS:NN POS:VBZ POS:VBN POS:IN POS:RB POS:CD POS:, POS:CD POS:NNS POS:CD POS:IN POS:CD POS:NNS POS:. 
[sentNum: 212]<Annotation Id="13147" Type="Sentence" StartNode="25361" EndNode="25620">Regarding the frequency of screening mammography, the United States Preventive Services Task Force also diverged from what has become common practice in the United States by recommending biennial rather than annual screening for women aged 50 years and older. PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:United States SemanticType:[geoa] PreferredName:Preventive service healthcare SemanticType:[hlca] PreferredName:Advisory Committees SemanticType:[gora] PreferredName:Common (qualifier value) SemanticType:[qnco] PreferredName:Practice Experience SemanticType:[menp] PreferredName:United States SemanticType:[geoa] PreferredName:Recommendation SemanticType:[idcn] PreferredName:annual screening SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] POS:VBG POS:DT POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:NNP POS:NNP POS:NNP POS:NNPS POS:NNP POS:NNP POS:RB POS:VBD POS:IN POS:WP POS:VBZ POS:VBN POS:JJ POS:NN POS:IN POS:DT POS:NNP POS:NNPS POS:IN POS:VBG POS:JJ POS:RB POS:IN POS:JJ POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:. 
[sentNum: 213]<Annotation Id="13148" Type="Sentence" StartNode="25621" EndNode="25887">This decision was based on the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network screening models, which predicted that 81% of the benefits of screening (ie, mortality reduction) could be maintained by screening every other year (24). PreferredName:Decision SemanticType:[menp] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:Intervention regimes SemanticType:[hlca] PreferredName:Surveillance Modeling SemanticType:[resa] PreferredName:Consortium or Network SemanticType:[prog] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Model SemanticType:[inpr] PreferredName:Prediction SemanticType:[idcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Maintaining (action) SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:per year SemanticType:[tmco] POS:DT POS:NN POS:VBD POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:NNP POS:NNP POS:NNPS POS:CC POS:NNP POS:NNP POS:NNP POS:NN POS:NNS POS:, POS:WDT POS:VBD POS:IN POS:CD POS:NN POS:IN POS:DT POS:NNS POS:IN POS:NN POS:( POS:NNP POS:, POS:NN POS:NN POS:) POS:MD POS:VB POS:VBN POS:IN POS:VBG POS:DT POS:JJ POS:NN POS:( POS:CD POS:) POS:. POS:POS 
[sentNum: 214]<Annotation Id="13149" Type="Sentence" StartNode="25888" EndNode="25991">This strategy is less resource intensive and is predicted to reduce false-positive results by 50% (23). PreferredName:strategy SemanticType:[menp] PreferredName:Less Than SemanticType:[inpr] PreferredName:Resources SemanticType:[idcn] PreferredName:Prediction SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Arabic numeral 23 SemanticType:[qnco] POS:DT POS:NN POS:VBZ POS:JJR POS:NN POS:NN POS:CC POS:VBZ POS:VBN POS:TO POS:VB POS:JJ POS:NNS POS:IN POS:CD POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 215]<Annotation Id="13150" Type="Sentence" StartNode="25992" EndNode="26223">However, these models demonstrate a greater reduction in mortality and increased number of life years gained by screening annually; therefore, accepting a biennial strategy reduces some (19%) of the potential benefits of screening.PreferredName:Model SemanticType:[inpr] PreferredName:Greater SemanticType:[qnco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Gain SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] PreferredName:Accepted SemanticType:[qlco] PreferredName:strategy SemanticType:[menp] PreferredName:Within SemanticType:[spco] PreferredName:Potential SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:RB POS:, POS:DT POS:NNS POS:VBP POS:DT POS:JJR POS:NN POS:IN POS:NN POS:CC POS:VBD POS:NN POS:IN POS:NN POS:NNS POS:VBD POS:IN POS:VBG POS:RB POS:: POS:RB POS:, POS:VBG POS:DT POS:JJ POS:NN POS:VBZ POS:DT POS:( POS:CD POS:NN POS:) POS:IN POS:DT POS:JJ POS:NNS POS:IN POS:NN POS:. 
[sentNum: 216]<Annotation Id="13151" Type="Sentence" StartNode="26229" EndNode="26298">What are the potential adverse consequences of screening mammography?PreferredName:Potential SemanticType:[qlco] PreferredName:Consequence of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] POS:WP POS:VBP POS:DT POS:JJ POS:JJ POS:NNS POS:IN POS:VBG POS:NNP POS:. 
[sentNum: 217]<Annotation Id="13152" Type="Sentence" StartNode="26300" EndNode="26446">Potential adverse outcomes of breast cancer screening mammography include false-positive mammograms, false-negative mammograms, and overdiagnosis. PreferredName:Potential SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Include (action) SemanticType:[acty] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:False Negative SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:overdiagnosis SemanticType:[fndg] POS:JJ POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:NN POS:NN POS:VBP POS:JJ POS:NNS POS:, POS:JJ POS:NNS POS:, POS:CC POS:NN POS:. 
[sentNum: 218]<Annotation Id="13153" Type="Sentence" StartNode="26447" EndNode="26661">Concerns about the risk of radiation exposure (eg, induction of breast cancer from radiation exposure) have largely been decreased by improvements in mammography technique, technology, and clinical experience (45).PreferredName:Concern SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Exposure to radiation SemanticType:[phpr] PreferredName:Egypt SemanticType:[geoa] PreferredName:Induction procedure SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Exposure to radiation SemanticType:[phpr] PreferredName:Reduced SemanticType:[qlco] PreferredName:Improvement SemanticType:[cnce] PreferredName:Mammography SemanticType:[diap] PreferredName:Technology SemanticType:[ocdi] PreferredName:Clinical SemanticType:[qlco] PreferredName:Practice Experience SemanticType:[menp] POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:( POS:NNP POS:, POS:NN POS:IN POS:NN POS:NN POS:IN POS:NN POS:NN POS:) POS:VBP POS:RB POS:VBN POS:VBN POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:, POS:NN POS:, POS:CC POS:JJ POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 219]<Annotation Id="13154" Type="Sentence" StartNode="26663" EndNode="26833">False-positive mammograms (ie, those with perceived abnormalities requiring further evaluation to verify that the lesion is not cancer) are a continuing concern (44, 46). PreferredName:False Positive SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:Perception SemanticType:[menp] PreferredName:teratologic SemanticType:[ftcn] PreferredName:Further SemanticType:[spco] PreferredName:Evaluation procedure SemanticType:[hlca] PreferredName:Verification SemanticType:[ftcn] PreferredName:Lesion SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Continuous SemanticType:[idcn] PreferredName:Concern SemanticType:[idcn] POS:JJ POS:NNS POS:( POS:NNP POS:, POS:DT POS:IN POS:VBN POS:NNS POS:VBG POS:JJ POS:NN POS:TO POS:VB POS:IN POS:DT POS:NN POS:VBZ POS:RB POS:NN POS:) POS:VBP POS:DT POS:VBG POS:NN POS:( POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 220]<Annotation Id="13155" Type="Sentence" StartNode="26834" EndNode="27033">False-positive screening mammograms require diagnostic mammography with supplementary views, ultrasonography, and even biopsy in 20–30% of cases in an attempt to reach an accurate diagnosis (44, 46). PreferredName:False Positive SemanticType:[lbtr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Diagnostic Mammography SemanticType:[diap] PreferredName:View SemanticType:[spco] PreferredName:Ultrasonography SemanticType:[diap] PreferredName:Biopsy SemanticType:[diap] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Attempt SemanticType:[evnt] PreferredName:Reaching SemanticType:[orgf] PreferredName:Diagnostic Accuracy SemanticType:[qlco] POS:JJ POS:NN POS:NNS POS:VBP POS:JJ POS:NN POS:IN POS:JJ POS:NNS POS:, POS:RB POS:, POS:CC POS:RB POS:JJ POS:IN POS:CD POS:NNS POS:CD POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NN POS:TO POS:VB POS:DT POS:JJ POS:NN POS:( POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 221]<Annotation Id="13156" Type="Sentence" StartNode="27034" EndNode="27201">Psychosocial consequences of screening mammography, such as anxiety and distress, have been identified, reviewed, and are generally short-lived and not severe (47–50). PreferredName:Treatment/Psychosocial Effects SemanticType:[fndg] PreferredName:Consequence of SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Anxiety SemanticType:[menp] PreferredName:Distress SemanticType:[menp] PreferredName:Identified SemanticType:[qlco] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Short SemanticType:[qnco] PreferredName:% live SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Severe (severity modifier) SemanticType:[qlco] POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:, POS:JJ POS:IN POS:NN POS:CC POS:NN POS:, POS:VBP POS:VBN POS:VBN POS:, POS:VBN POS:, POS:CC POS:VBP POS:RB POS:JJ POS:CC POS:RB POS:JJ POS:( POS:$ POS:CD POS:CD POS:) POS:. 
[sentNum: 222]<Annotation Id="13157" Type="Sentence" StartNode="27202" EndNode="27498">Studies evaluating the effect of false-positive results suggest that women in the United States are highly tolerant of false-positive mammograms, and that women who experience a false-positive mammogram are more likely than women with a normal result to adhere to routine screening in the future. PreferredName:Scientific Study SemanticType:[lbpr] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Effect SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:suggestion SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:United States SemanticType:[geoa] PreferredName:High SemanticType:[qlco] PreferredName:Tolerant SemanticType:[ftcn] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Practice Experience SemanticType:[menp] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Mammography SemanticType:[diap] PreferredName:More SemanticType:[ftcn] PreferredName:Probably SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Normal result SemanticType:[fndg] PreferredName:Immobile SemanticType:[fndg] PreferredName:Routine SemanticType:[qlco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Future SemanticType:[tmco] POS:NNS POS:VBG POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:VBP POS:IN POS:NNS POS:IN POS:DT POS:NNP POS:NNPS POS:VBP POS:RB POS:JJ POS:IN POS:JJ POS:NNS POS:, POS:CC POS:IN POS:NNS POS:WP POS:VBP POS:DT POS:JJ POS:NN POS:VBP POS:RBR POS:JJ POS:IN POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:TO POS:VB POS:TO POS:JJ POS:NN POS:IN POS:DT POS:NN POS:. 
[sentNum: 223]<Annotation Id="13158" Type="Sentence" StartNode="27499" EndNode="27650">Women with false-positive results were more likely to have anxiety about developing breast cancer, but not at a demonstrably pathologic level (50, 51).PreferredName:Woman SemanticType:[popg] PreferredName:False Positive SemanticType:[lbtr] PreferredName:More SemanticType:[ftcn] PreferredName:Probably SemanticType:[idcn] PreferredName:Anxiety SemanticType:[menp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Negation SemanticType:[ftcn] PreferredName:Pathologic SemanticType:[ftcn] PreferredName:Disease classification level SemanticType:[clas] POS:NNP POS:IN POS:JJ POS:NNS POS:VBD POS:RBR POS:JJ POS:TO POS:VB POS:NN POS:IN POS:VBG POS:NN POS:NN POS:, POS:CC POS:RB POS:IN POS:DT POS:RB POS:JJ POS:NN POS:( POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 224]<Annotation Id="13159" Type="Sentence" StartNode="27656" EndNode="27732">What are the factors that increase a woman's relative risk of breast cancer?PreferredName:Factor SemanticType:[ftcn] PreferredName:Increase SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:WP POS:VBP POS:DT POS:NNS POS:WDT POS:VBP POS:DT POS:NN POS:JJ POS:NN POS:IN POS:NN POS:NN POS:. POS:POS 
[sentNum: 225]<Annotation Id="13160" Type="Sentence" StartNode="27734" EndNode="27983">Most women in whom invasive breast cancer is diagnosed do not have unique identifiable risk factors; however, women with certain characteristics do have an increased lifetime prevalence of breast cancer compared with the general population (52, 53). PreferredName:Most SemanticType:[qnco] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Invasive SemanticType:[qlco] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Unique SemanticType:[qlco] PreferredName:Identifiable Class SemanticType:[cnce] PreferredName:risk factors SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Statistical Prevalence SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Comparison SemanticType:[acty] PreferredName:General Population SemanticType:[popg] POS:JJS POS:NNS POS:IN POS:WP POS:JJ POS:NN POS:NN POS:VBZ POS:VBN POS:VBP POS:RB POS:VB POS:JJ POS:JJ POS:NN POS:NNS POS:: POS:RB POS:, POS:NNS POS:IN POS:JJ POS:NNS POS:VBP POS:VB POS:DT POS:VBN POS:NN POS:NN POS:IN POS:NN POS:NN POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:( POS:CD POS:, POS:CD POS:) POS:. 
[sentNum: 226]<Annotation Id="13161" Type="Sentence" StartNode="27984" EndNode="28048">The incidence of breast cancer increases with advancing age (2). PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Increase SemanticType:[ftcn] PreferredName:Advance SemanticType:[medd] PreferredName:Age SemanticType:[orga] PreferredName:2+ Score SemanticType:[qnco] POS:DT POS:NN POS:IN POS:NN POS:NN POS:NNS POS:IN POS:VBG POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 227]<Annotation Id="13162" Type="Sentence" StartNode="28049" EndNode="28234">Because women at high risk need to be appropriately counseled regarding increased surveillance or breast cancer risk reduction, physicians should periodically assess breast cancer risk. PreferredName:Woman SemanticType:[popg] PreferredName:High risk of SemanticType:[qlco] PreferredName:Needs SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Counsel - legal SemanticType:[prog] PreferredName:Increase SemanticType:[ftcn] PreferredName:Medical Surveillance SemanticType:[hlca] PreferredName:Reduction mammaplasty SemanticType:[topp] PreferredName:Cancer Risk SemanticType:[qnco] PreferredName:Physicians SemanticType:[prog] PreferredName:Periodic SemanticType:[tmco] PreferredName:Assessed SemanticType:[acty] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:VBP POS:TO POS:VB POS:RB POS:VBN POS:VBG POS:JJ POS:NN POS:CC POS:NN POS:NN POS:NN POS:NN POS:, POS:NNS POS:MD POS:RB POS:VB POS:NN POS:NN POS:NN POS:. 
[sentNum: 228]<Annotation Id="13163" Type="Sentence" StartNode="28235" EndNode="28360">The goal of this risk assessment is to categorize the woman's risk level as average for her age versus elevated or high risk. PreferredName:objective (goal) SemanticType:[inpr] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:To SemanticType:[qlco] PreferredName:categorizing SemanticType:[acty] PreferredName:Woman SemanticType:[popg] PreferredName:Risk SemanticType:[qlco] PreferredName:Disease classification level SemanticType:[clas] PreferredName:Average SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:High SemanticType:[qlco] PreferredName:High risk of SemanticType:[qlco] POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBZ POS:TO POS:VB POS:DT POS:NN POS:NN POS:NN POS:IN POS:NN POS:IN POS:PRP$ POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:. POS:POS 
[sentNum: 229]<Annotation Id="13164" Type="Sentence" StartNode="28361" EndNode="28645">Risk assessment should not be used to consider a woman ineligible for screening appropriate for her age, but rather to identify those who may qualify for enhanced screening, such as addition of MRI screening or more frequent clinical breast examinations and risk reduction strategies.PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Negation SemanticType:[ftcn] PreferredName:Used by SemanticType:[fndg] PreferredName:To SemanticType:[qlco] PreferredName:consider SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Appropriate SemanticType:[qlco] PreferredName:Age SemanticType:[orga] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:More SemanticType:[ftcn] PreferredName:Frequent SemanticType:[tmco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Risk Reduction SemanticType:[inbe] PreferredName:strategy SemanticType:[menp] POS:NN POS:NN POS:MD POS:RB POS:VB POS:VBN POS:TO POS:VB POS:DT POS:NN POS:NN POS:IN POS:VBG POS:JJ POS:IN POS:PRP$ POS:NN POS:, POS:CC POS:RB POS:TO POS:VB POS:DT POS:WP POS:MD POS:VB POS:IN POS:JJ POS:NN POS:, POS:JJ POS:IN POS:NN POS:IN POS:JJ POS:NN POS:CC POS:RBR POS:JJ POS:JJ POS:NN POS:NNS POS:CC POS:NN POS:NN POS:NNS POS:. 
[sentNum: 230]<Annotation Id="13165" Type="Sentence" StartNode="28647" EndNode="28655">Table 4. PreferredName:Table - furniture SemanticType:[mnob] POS:$ POS:CD POS:. 
[sentNum: 231]<Annotation Id="13166" Type="Sentence" StartNode="28656" EndNode="28721">Factors That Increase the Relative Risk of Breast Cancer in WomenPreferredName:Factor SemanticType:[ftcn] PreferredName:Increase SemanticType:[ftcn] PreferredName:Relative Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Woman SemanticType:[popg] POS:VB POS:DT POS:VBP POS:DT POS:NNP POS:NNP POS:IN POS:NNP POS:NNP POS:IN POS:NNP 
[sentNum: 232]<Annotation Id="13167" Type="Sentence" StartNode="28723" EndNode="28736">Relative Risk PreferredName:Relative Risk SemanticType:[qnco] POS:NNP POS:NNP 
[sentNum: 233]<Annotation Id="13168" Type="Sentence" StartNode="28740" EndNode="28746">FactorPreferredName:Factor SemanticType:[ftcn] POS:NN 
[sentNum: 234]<Annotation Id="13169" Type="Sentence" StartNode="28748" EndNode="28752">&gt;4.0 POS:RB POS:CD POS:. POS:JJR 
[sentNum: 235]<Annotation Id="13170" Type="Sentence" StartNode="28756" EndNode="28762">FemalePreferredName:Woman SemanticType:[popg] POS:NNP 
[sentNum: 236]<Annotation Id="13171" Type="Sentence" StartNode="28764" EndNode="28840">Age (65+ vs &lt;65 years, although risk increases across all ages until age 80)PreferredName:Age SemanticType:[orga] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:Arabic numeral 65 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Risk SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Age SemanticType:[orga] POS:NNP POS:( POS:CD POS:NN POS:VBP POS:CD POS:CD POS:NNS POS:, POS:IN POS:NN POS:VBZ POS:IN POS:DT POS:NNS POS:IN POS:NN POS:CD POS:) 
[sentNum: 237]<Annotation Id="13172" Type="Sentence" StartNode="28842" EndNode="28916">Certain inherited genetic mutations for breast cancer (BRCA1 and/or BRCA2)PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:Breast Cancer, Familial SemanticType:[neop] PreferredName:Mutation SemanticType:[genf] PreferredName:BRCA2 gene SemanticType:[gngm] POS:JJ POS:VBD POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:( POS:NNP POS:CD POS:CC POS:NNS POS:CC POS:NNP POS:CD POS:) 
[sentNum: 238]<Annotation Id="13173" Type="Sentence" StartNode="28918" EndNode="28997">Two or more first-degree relatives with breast cancer diagnosed at an early agePreferredName:Two SemanticType:[qnco] PreferredName:More SemanticType:[ftcn] PreferredName:Number of First Degree Relatives (Affected) SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Early SemanticType:[tmco] PreferredName:Age SemanticType:[orga] POS:CD POS:CC POS:JJR POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:VBN POS:IN POS:DT POS:JJ POS:NN 
[sentNum: 239]<Annotation Id="13174" Type="Sentence" StartNode="28999" EndNode="29032">Personal history of breast cancerPreferredName:Social and personal history SemanticType:[fndg] PreferredName:Atypical hyperplasia of breast SemanticType:[patf] PreferredName:Cancer confirmed SemanticType:[fndg] POS:VB POS:NN POS:IN POS:NN POS:NN 
[sentNum: 240]<Annotation Id="13175" Type="Sentence" StartNode="29034" EndNode="29060">High breast tissue densityPreferredName:High SemanticType:[qlco] PreferredName:Body tissue SemanticType:[tisu] PreferredName:density SemanticType:[qnco] POS:JJ POS:NN POS:NN POS:NNS 
[sentNum: 241]<Annotation Id="13176" Type="Sentence" StartNode="29062" EndNode="29099">Biopsy-confirmed atypical hyperplasiaPreferredName:Biopsy SemanticType:[diap] POS:VBN POS:JJ POS:NN 
[sentNum: 242]<Annotation Id="13177" Type="Sentence" StartNode="29101" EndNode="29108">2.1–4.0 POS:CD POS:. POS:CD POS:NNP POS:CD POS:. POS:CD 
[sentNum: 243]<Annotation Id="13178" Type="Sentence" StartNode="29112" EndNode="29156">One first-degree relative with breast cancerPreferredName:One SemanticType:[qnco] PreferredName:First Degree Relative SemanticType:[famg] PreferredName:With - dosing instruction fragment SemanticType:[inpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:CD POS:NN POS:JJ POS:IN POS:NN POS:NN 
[sentNum: 244]<Annotation Id="13179" Type="Sentence" StartNode="29158" EndNode="29186">High-dose radiation to chestPreferredName:High-LET Radiotherapy SemanticType:[topp] POS:VB POS:NN POS:TO POS:NN 
[sentNum: 245]<Annotation Id="13180" Type="Sentence" StartNode="29188" EndNode="29222">High bone density (postmenopausal)PreferredName:Bone Mineral Density Test SemanticType:[diap] PreferredName:Postmenopausal state SemanticType:[tmco] POS:JJ POS:NN POS:NNS POS:( POS:NN POS:) 
[sentNum: 246]<Annotation Id="13181" Type="Sentence" StartNode="29224" EndNode="29231">1.1–2.0PreferredName:Phase I/II Trial SemanticType:[resa] POS:CD POS:. POS:CD POS:NNP POS:CD POS:. POS:CD 
[sentNum: 247]<Annotation Id="13182" Type="Sentence" StartNode="29233" EndNode="29273">Factors that affect circulating hormones PreferredName:Factor SemanticType:[ftcn] PreferredName:Affect (mental function) SemanticType:[menp] PreferredName:Circulating SemanticType:[ftcn] PreferredName:Hormones SemanticType:[horm] POS:NNS POS:WDT POS:VBP POS:JJ POS:NNS 
[sentNum: 248]<Annotation Id="13183" Type="Sentence" StartNode="29277" EndNode="29326">Late age at first full-term pregnancy (&gt;30 years)PreferredName:Late SemanticType:[tmco] PreferredName:Age at First Live Birth SemanticType:[clna] PreferredName:year SemanticType:[tmco] POS:JJ POS:NN POS:IN POS:JJ POS:JJ POS:NN POS:( POS:CD POS:CD POS:NNS POS:) 
[sentNum: 249]<Annotation Id="13184" Type="Sentence" StartNode="29328" EndNode="29354">Early menarche (&lt;12 years)PreferredName:Early menarche SemanticType:[fndg] PreferredName:year SemanticType:[tmco] POS:NN POS:NN POS:( POS:CD POS:CD POS:NNS POS:) 
[sentNum: 250]<Annotation Id="13185" Type="Sentence" StartNode="29356" EndNode="29382">Late menopause (&gt;55 years)PreferredName:Late SemanticType:[tmco] PreferredName:Menopause SemanticType:[phsf] PreferredName:Arabic numeral 55 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] POS:JJ POS:NN POS:( POS:VB POS:CD POS:NNS POS:) 
[sentNum: 251]<Annotation Id="13186" Type="Sentence" StartNode="29384" EndNode="29408">No full-term pregnanciesPreferredName:Full Term finding SemanticType:[fndg] PreferredName:Pregnancies:Number:Point in time:^Patient:Quantitative:Reported SemanticType:[clna] POS:DT POS:JJ POS:NNS 
[sentNum: 252]<Annotation Id="13187" Type="Sentence" StartNode="29410" EndNode="29433">Never breastfed a childPreferredName:Never (frequency) SemanticType:[tmco] PreferredName:Breast Feeding SemanticType:[orgf] PreferredName:Offspring SemanticType:[famg] POS:RB POS:VB POS:DT POS:NN 
[sentNum: 253]<Annotation Id="13188" Type="Sentence" StartNode="29435" EndNode="29464">Recent oral contraceptive usePreferredName:Recent SemanticType:[tmco] PreferredName:ORAL CONTRACEPTIVE INGESTION SemanticType:[fndg] POS:VBN POS:JJ POS:JJ POS:NN 
[sentNum: 254]<Annotation Id="13189" Type="Sentence" StartNode="29466" EndNode="29516">Recent and long-term use of estrogen and progestinPreferredName:Recent SemanticType:[tmco] PreferredName:Long-term SemanticType:[tmco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Estrogens SemanticType:[horm, phsu, strd] PreferredName:Progestins SemanticType:[horm, phsu, strd] POS:JJ POS:CC POS:JJ POS:NN POS:IN POS:NN POS:CC POS:NN 
[sentNum: 255]<Annotation Id="13190" Type="Sentence" StartNode="29518" EndNode="29542">Obesity (postmenopausal)PreferredName:Obesity SemanticType:[dsyn] PreferredName:Postmenopausal state SemanticType:[tmco] POS:VB POS:( POS:NN POS:) 
[sentNum: 256]<Annotation Id="13191" Type="Sentence" StartNode="29544" EndNode="29557">Other factors PreferredName:Other Personal Medical History SemanticType:[orga] PreferredName:Factor SemanticType:[ftcn] POS:JJ POS:NNS 
[sentNum: 257]<Annotation Id="13192" Type="Sentence" StartNode="29561" EndNode="29610">Personal history of endometrial or ovarian cancerPreferredName:Personal Attribute SemanticType:[orga] PreferredName:Endometrial SemanticType:[spco] PreferredName:Malignant neoplasm of ovary SemanticType:[neop] POS:JJ POS:NN POS:IN POS:NN POS:CC POS:NN POS:NN 
[sentNum: 258]<Annotation Id="13193" Type="Sentence" StartNode="29612" EndNode="29631">Alcohol consumptionPreferredName:Alcohol consumption SemanticType:[inbe] POS:NN POS:NN 
[sentNum: 259]<Annotation Id="13194" Type="Sentence" StartNode="29633" EndNode="29646">Height (tall)PreferredName:Height SemanticType:[orga] PreferredName:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma SemanticType:[neop] POS:NNP POS:( POS:JJ POS:) 
[sentNum: 260]<Annotation Id="13195" Type="Sentence" StartNode="29648" EndNode="29673">High socioeconomic statusPreferredName:High SemanticType:[qlco] PreferredName:Socioeconomic Status SemanticType:[qlco] POS:JJ POS:NN POS:NNS 
[sentNum: 261]<Annotation Id="13196" Type="Sentence" StartNode="29675" EndNode="29700">Ashkenazi Jewish heritagePreferredName:Ashkenazi Jew, follower of religion SemanticType:[popg] PreferredName:Heritage SemanticType:[clas] POS:VB POS:JJ POS:NN 
[sentNum: 262]<Annotation Id="13197" Type="Sentence" StartNode="29702" EndNode="29757">Reprinted with permission from American Cancer Society. PreferredName:Reprint SemanticType:[inpr] PreferredName:Authorization documentation SemanticType:[inpr] PreferredName:American Cancer Society SemanticType:[pros] POS:VBN POS:IN POS:NNS POS:IN POS:NNP POS:NNP POS:NNP POS:. 
[sentNum: 263]<Annotation Id="13198" Type="Sentence" StartNode="29758" EndNode="29798">Breast Cancer Facts &amp; Figures 2009-2010. PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:2010s SemanticType:[tmco] POS:NNP POS:NNP POS:NNP POS:CC POS:NNP POS:CD POS:: POS:NNP POS:. 
[sentNum: 264]<Annotation Id="13199" Type="Sentence" StartNode="29799" EndNode="29837">Atlanta: American Cancer Society, Inc. PreferredName:Atlanta SemanticType:[euka] PreferredName:American Cancer Society SemanticType:[pros] POS:NNP POS:: POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:. 
[sentNum: 265]<Annotation Id="13200" Type="Sentence" StartNode="29838" EndNode="29888">Adapted with permission from Hulka BS, Moorman PG. PreferredName:Adapt (substance) SemanticType:[orch] PreferredName:Authorization documentation SemanticType:[inpr] PreferredName:Moorman SemanticType:[hcro] PreferredName:Prostaglandin measurement SemanticType:[lbpr] POS:VBN POS:IN POS:NNS POS:IN POS:NNP POS:NNP POS:, POS:NNP POS:NNP POS:. 
[sentNum: 266]<Annotation Id="13201" Type="Sentence" StartNode="29889" EndNode="29936">Breast cancer: hormones and other risk factors. PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Hormones SemanticType:[horm] PreferredName:risk factors SemanticType:[qnco] POS:JJ POS:NN POS:: POS:NNS POS:CC POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 267]<Annotation Id="13202" Type="Sentence" StartNode="29937" EndNode="29947">Maturitas. POS:NN POS:. 
[sentNum: 268]<Annotation Id="13203" Type="Sentence" StartNode="29948" EndNode="29994">Feb 28 2001;38(1):103–113; discussion 113–106.PreferredName:1+ Score SemanticType:[qnco] PreferredName:Discussion (procedure) SemanticType:[topp] POS:NNP POS:CD POS:CD POS:: POS:CD POS:( POS:CD POS:) POS:: POS:CD POS:NNP POS:CD POS:: POS:NN POS:CD POS:CD POS:CD POS:. 
[sentNum: 269]<Annotation Id="13204" Type="Sentence" StartNode="29996" EndNode="30021">Reproductive Risk FactorsPreferredName:Reproductive History SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] POS:NNP POS:NNP POS:NNP 
[sentNum: 270]<Annotation Id="13205" Type="Sentence" StartNode="30023" EndNode="30188">Certain reproductive factors also influence breast cancer risk, including age at menarche, age at first birth, breastfeeding, parity, and age at menopause (Table 4). PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Age at menarche SemanticType:[fndg] PreferredName:Age SemanticType:[orga] PreferredName:First Birth SemanticType:[tmco] PreferredName:Breast Feeding SemanticType:[orgf] PreferredName:Parity:Number:Point in time:^Patient:Quantitative:Reported SemanticType:[clna] PreferredName:Age at menopause:Time:Point in time:^Patient:Quantitative SemanticType:[clna] PreferredName:Table - furniture SemanticType:[mnob] POS:JJ POS:JJ POS:NNS POS:RB POS:VBP POS:NN POS:NN POS:NN POS:, POS:VBG POS:NN POS:IN POS:NN POS:, POS:NN POS:IN POS:JJ POS:NN POS:, POS:NN POS:, POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:( POS:NNP POS:CD POS:) POS:. 
[sentNum: 271]<Annotation Id="13206" Type="Sentence" StartNode="30189" EndNode="30325">A greater number of reproductive years, later age at first birth, and lower parity or nulliparity generally increase breast cancer risk.PreferredName:Greater SemanticType:[qnco] PreferredName:Numbers SemanticType:[qnco] PreferredName:REPRODUCTIVE SemanticType:[clas] PreferredName:year SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:First Birth SemanticType:[tmco] PreferredName:Lower - spatial qualifier SemanticType:[spco] PreferredName:Parity:Number:Point in time:^Patient:Quantitative:Reported SemanticType:[clna] PreferredName:Nulliparity SemanticType:[orgf] PreferredName:Increase SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] POS:DT POS:JJR POS:NN POS:IN POS:JJ POS:NNS POS:, POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:, POS:CC POS:JJR POS:NN POS:CC POS:NN POS:RB POS:VBP POS:NN POS:NN POS:NN POS:. 
[sentNum: 272]<Annotation Id="13207" Type="Sentence" StartNode="30327" EndNode="30348">Familial Risk FactorsPreferredName:Familial risk factor SemanticType:[qlco] POS:NNP POS:NNP POS:NNP 
[sentNum: 273]<Annotation Id="13208" Type="Sentence" StartNode="30350" EndNode="30696">Another important consideration in breast cancer risk assessment is family history to identify cases of breast cancer, ovarian cancer, prostate cancer, and other types of cancer in first-degree relatives (parents, sibling, child), second-degree relatives, and third-degree relatives, including the age of onset for the family members with cancer. PreferredName:consideration SemanticType:[fndg] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Assessment for risk of cancer SemanticType:[hlca] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Malignant neoplasm of ovary SemanticType:[neop] PreferredName:Malignant neoplasm of prostate SemanticType:[neop] PreferredName:Other SemanticType:[qlco] PreferredName:Type - attribute SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Number of First Degree Relatives (Affected) SemanticType:[qnco] PreferredName:parent SemanticType:[famg] PreferredName:Sibling - RoleCode SemanticType:[inpr] PreferredName:Offspring SemanticType:[famg] PreferredName:Second Degree Relative SemanticType:[famg] PreferredName:Third Degree Relative SemanticType:[humn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Age of Onset SemanticType:[qnco] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Family member SemanticType:[famg] PreferredName:Primary malignant neoplasm SemanticType:[neop] POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NN POS:NN POS:VBZ POS:NN POS:NN POS:TO POS:VB POS:NNS POS:IN POS:NN POS:NN POS:, POS:NN POS:NN POS:, POS:NN POS:NN POS:, POS:CC POS:JJ POS:NNS POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:( POS:NNS POS:, POS:NN POS:, POS:NN POS:) POS:, POS:JJ POS:NNS POS:, POS:CC POS:JJ POS:NNS POS:, POS:VBG POS:DT POS:NN POS:IN POS:NN POS:IN POS:DT POS:NN POS:NNS POS:IN POS:NN POS:. 
[sentNum: 274]<Annotation Id="13209" Type="Sentence" StartNode="30697" EndNode="30902">Based on this family history, women may be eligible for testing for BRCA gene mutations or for referral to a genetic counselor for further evaluation and consideration of testing (see Practice Bulletin No.103PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:eligible SemanticType:[idcn] PreferredName:Testing SemanticType:[ftcn] PreferredName:brca gene SemanticType:[gngm] PreferredName:Mutation SemanticType:[genf] PreferredName:Patient referral SemanticType:[hlca] PreferredName:To SemanticType:[qlco] PreferredName:Genetic counselor SemanticType:[prog] PreferredName:Further SemanticType:[spco] PreferredName:Evaluation procedure SemanticType:[hlca] PreferredName:consideration SemanticType:[fndg] PreferredName:Testing SemanticType:[ftcn] PreferredName:Vision SemanticType:[orgf] PreferredName:Practice Experience SemanticType:[menp] POS:VBN POS:IN POS:DT POS:NN POS:NN POS:, POS:NNS POS:MD POS:VB POS:JJ POS:IN POS:VBG POS:IN POS:NNP POS:NN POS:NNS POS:CC POS:IN POS:NN POS:TO POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:CC POS:NN POS:IN POS:NN POS:( POS:VB POS:NNP POS:NNP POS:NNP POS:. 
[sentNum: 275]<Annotation Id="13210" Type="Sentence" StartNode="30902" EndNode="30966">103, Hereditary Breast and Ovarian Cancer Syndrome, April 2009).PreferredName:Hereditary SemanticType:[ftcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Malignant neoplasm of ovary SemanticType:[neop] PreferredName:Syndrome SemanticType:[dsyn] POS:NNP POS:, POS:NNP POS:NNP POS:CC POS:NNP POS:NNP POS:NNP POS:, POS:NNP POS:CD POS:) POS:. 
[sentNum: 276]<Annotation Id="13211" Type="Sentence" StartNode="30968" EndNode="30984">Combined FactorsPreferredName:Combined SemanticType:[qlco] PreferredName:Factor SemanticType:[ftcn] POS:JJ POS:NNS 
[sentNum: 277]<Annotation Id="13212" Type="Sentence" StartNode="30986" EndNode="31235">The Gail Model is a risk assessment tool that uses patient age, some reproductive factors, limited family history (breast cancer in first-degree female relatives), and a history of breast biopsies to estimate 5-year and lifetime breast cancer risks. PreferredName:Gail Risk Model SemanticType:[inpr] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Scientific Equipment SemanticType:[mnob] PreferredName:utilization qualifier SemanticType:[ftcn] PreferredName:Patients SemanticType:[podg] PreferredName:Age SemanticType:[orga] PreferredName:Reproductive History SemanticType:[fndg] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Number of First Degree Relatives (Affected) SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Historical aspects qualifier SemanticType:[inpr] PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:Estimated SemanticType:[qnco] PreferredName:&gt;5 SemanticType:[qnco] PreferredName:per year SemanticType:[tmco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:DT POS:NNP POS:NNP POS:VBZ POS:DT POS:NN POS:NN POS:NN POS:WDT POS:VBZ POS:JJ POS:NN POS:, POS:DT POS:JJ POS:NNS POS:, POS:JJ POS:NN POS:NN POS:( POS:NN POS:NN POS:IN POS:JJ POS:JJ POS:NNS POS:) POS:, POS:CC POS:DT POS:NN POS:IN POS:NN POS:NNS POS:TO POS:VB POS:CD POS:JJ POS:NN POS:CC POS:NN POS:NN POS:NN POS:NNS POS:. 
[sentNum: 278]<Annotation Id="13213" Type="Sentence" StartNode="31236" EndNode="31335">This model has been validated in Caucasian women and studied extensively in African American women. PreferredName:Model SemanticType:[inpr] PreferredName:Caucasoid Race SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Study SemanticType:[resa] PreferredName:African American SemanticType:[popg] PreferredName:Woman SemanticType:[popg] POS:DT POS:NN POS:VBZ POS:VBN POS:VBN POS:IN POS:JJ POS:NNS POS:CC POS:VBN POS:RB POS:IN POS:JJ POS:JJ POS:NNS POS:. 
[sentNum: 279]<Annotation Id="13214" Type="Sentence" StartNode="31336" EndNode="31444">The assessment can be completed in less than a minute, and is available at http://www.cancer.gov/bcrisktool. PreferredName:Evaluation procedure SemanticType:[hlca] PreferredName:Complete SemanticType:[qlco] PreferredName:/minute SemanticType:[tmco] PreferredName:Availability of SemanticType:[ftcn] PreferredName:HTTP SemanticType:[idcn] PreferredName:Internet SemanticType:[mnob] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:RAB3D gene SemanticType:[gngm] POS:DT POS:NN POS:MD POS:VB POS:VBN POS:IN POS:JJR POS:IN POS:DT POS:NN POS:, POS:CC POS:VBZ POS:JJ POS:IN POS:NN POS:: POS:JJ POS:JJ POS:NN POS:. POS:NN POS:. POS:NNP POS:VBZ POS:NN POS:. 
[sentNum: 280]<Annotation Id="13215" Type="Sentence" StartNode="31445" EndNode="31769">Women estimated to have a 5-year breast cancer risk of 1.7% or greater (equivalent to the average risk for a women aged 60 years) or a lifetime risk of 20% or greater may be offered enhanced screening, including a clinical breast examination every 6–12 months, yearly mammography, and instruction in breast self-examination. PreferredName:Woman SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:A 7 SemanticType:[orch, phsu] PreferredName:per year SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Greater SemanticType:[qnco] PreferredName:Equal SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Greater SemanticType:[qnco] PreferredName:Offered SemanticType:[fndg] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Distance vision 6/12 SemanticType:[fndg] PreferredName:month SemanticType:[tmco] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Breast Self-Examination SemanticType:[diap] POS:NNP POS:VBD POS:TO POS:VB POS:DT POS:CD POS:: POS:NN POS:NN POS:NN POS:NN POS:IN POS:CD POS:. POS:CD POS:NN POS:CC POS:JJR POS:( POS:JJ POS:TO POS:DT POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:VBN POS:CD POS:NNS POS:) POS:CC POS:DT POS:NN POS:NN POS:IN POS:CD POS:NN POS:CC POS:JJR POS:MD POS:VB POS:VBN POS:JJ POS:NN POS:, POS:VBG POS:DT POS:JJ POS:NN POS:NN POS:DT POS:CD POS:JJ POS:CD POS:NNS POS:, POS:JJ POS:NN POS:, POS:CC POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 281]<Annotation Id="13216" Type="Sentence" StartNode="31770" EndNode="32009">The Gail model is not a good risk assessment tool when there is a strong family history of breast cancer in women other than the mother and sisters of the patient or a family history of cancer other than breast cancer (eg, ovarian cancer). PreferredName:Gail Risk Model SemanticType:[inpr] PreferredName:Negation SemanticType:[ftcn] PreferredName:Good SemanticType:[qlco] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Scientific Equipment SemanticType:[mnob] PreferredName:Strong SemanticType:[qlco] PreferredName:Family history of breast cancer SemanticType:[fndg] PreferredName:Present SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Mother (person) SemanticType:[famg] PreferredName:Sister SemanticType:[famg] PreferredName:Patients SemanticType:[podg] PreferredName:Family history of cancer SemanticType:[fndg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Egypt SemanticType:[geoa] PreferredName:Malignant neoplasm of ovary SemanticType:[neop] POS:DT POS:NNP POS:NN POS:VBZ POS:RB POS:DT POS:JJ POS:NN POS:NN POS:NN POS:WRB POS:EX POS:VBZ POS:DT POS:JJ POS:NN POS:NN POS:IN POS:NN POS:NN POS:IN POS:NNS POS:JJ POS:IN POS:DT POS:NN POS:CC POS:NNS POS:IN POS:DT POS:NN POS:CC POS:DT POS:NN POS:NN POS:IN POS:NN POS:JJ POS:IN POS:NN POS:NN POS:( POS:NN POS:, POS:NN POS:NN POS:) POS:. 
[sentNum: 282]<Annotation Id="13217" Type="Sentence" StartNode="32010" EndNode="32074">Breast MRI is not typically recommended based on the Gail Model.PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Gail Risk Model SemanticType:[inpr] POS:NN POS:NN POS:VBZ POS:RB POS:RB POS:VBN POS:VBN POS:IN POS:DT POS:NNP POS:NNP POS:. 
[sentNum: 283]<Annotation Id="13218" Type="Sentence" StartNode="32080" EndNode="32133">What screening is appropriate for women at high risk?PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Appropriate SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:High risk of SemanticType:[qlco] POS:WDT POS:NN POS:VBZ POS:JJ POS:IN POS:NNS POS:IN POS:JJ POS:NN POS:. 
[sentNum: 284]<Annotation Id="13219" Type="Sentence" StartNode="32135" EndNode="32271">For women who test positive for BRCA1 or BRCA2 mutations, enhanced screening should be recommended and risk reduction methods discussed. PreferredName:Woman SemanticType:[popg] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Positive Finding SemanticType:[fndg] PreferredName:BRCA2 Gene Mutation SemanticType:[comd] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Risk Reduction SemanticType:[inbe] PreferredName:Methods aspects SemanticType:[inpr] POS:IN POS:NNS POS:WP POS:VBP POS:JJ POS:IN POS:NNP POS:CD POS:CC POS:NNP POS:CD POS:NNS POS:, POS:JJ POS:NN POS:MD POS:VB POS:VBN POS:CC POS:NN POS:NN POS:NNS POS:VBD POS:. 
[sentNum: 285]<Annotation Id="13220" Type="Sentence" StartNode="32272" EndNode="32441">Enhanced screening for these women includes twice-yearly clinical breast examinations, annual mammography, annual breast MRI, and instruction in breast self-examination. PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Include (action) SemanticType:[acty] PreferredName:Twice per year SemanticType:[tmco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Breast Self-Examination SemanticType:[diap] POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:VBZ POS:JJ POS:JJ POS:NN POS:NNS POS:, POS:JJ POS:NN POS:, POS:JJ POS:NN POS:NNP POS:, POS:CC POS:NN POS:IN POS:NN POS:NN POS:. 
[sentNum: 286]<Annotation Id="13221" Type="Sentence" StartNode="32442" EndNode="32542">(Details regarding the management of women with BRCA mutations are reviewed in Practice Bulletin No.103PreferredName:Details SemanticType:[qlco] PreferredName:Management procedure SemanticType:[ocac] PreferredName:Woman SemanticType:[popg] PreferredName:Mutation SemanticType:[genf] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Present SemanticType:[qnco] PreferredName:Practice Experience SemanticType:[menp] POS:( POS:NNS POS:VBG POS:DT POS:NN POS:IN POS:NNS POS:IN POS:NNP POS:NNS POS:VBP POS:VBN POS:IN POS:NNP POS:NNP POS:NNP POS:. 
[sentNum: 287]<Annotation Id="13222" Type="Sentence" StartNode="32542" EndNode="32605">103, Hereditary Breast and Ovarian Cancer Syndrome, April 2009.)PreferredName:Hereditary SemanticType:[ftcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Malignant neoplasm of ovary SemanticType:[neop] PreferredName:Syndrome SemanticType:[dsyn] POS:CD POS:, POS:NNP POS:NNP POS:CC POS:NNP POS:NNP POS:NNS POS:, POS:NNP POS:CD POS:. 
[sentNum: 288]<Annotation Id="13223" Type="Sentence" StartNode="32605" EndNode="32775">) Women who have first-degree relatives with these mutations but who are untested are generally managed as if they carry these mutations until their BRCA status is known.PreferredName:Woman SemanticType:[popg] PreferredName:Number of First Degree Relatives (Affected) SemanticType:[qnco] PreferredName:Mutation SemanticType:[genf] PreferredName:Management procedure SemanticType:[ocac] PreferredName:Carrying SemanticType:[acty] PreferredName:Theses SemanticType:[inpr] PreferredName:Mutation SemanticType:[genf] PreferredName:Status SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] POS:NNP POS:NNP POS:WP POS:VBP POS:JJ POS:NNS POS:IN POS:DT POS:NNS POS:CC POS:WP POS:VBP POS:JJ POS:VBP POS:RB POS:VBN POS:IN POS:IN POS:PRP POS:VBP POS:DT POS:NNS POS:IN POS:PRP$ POS:NNP POS:NN POS:VBZ POS:VBN POS:. 
[sentNum: 289]<Annotation Id="13224" Type="Sentence" StartNode="32777" EndNode="33118">Women who are estimated to have a lifetime risk of breast cancer of 20% or greater, based on risk models that rely largely on family history (such as BRCAPRO, BODACEA, or Claus), but who are either untested or test negative for BRCA gene mutations, can be offered enhanced screening as described previously for carriers of the BRCA mutation. PreferredName:Woman SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Greater SemanticType:[qnco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Model SemanticType:[inpr] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:BRCAPRO SemanticType:[inpr] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Negative SemanticType:[qlco] PreferredName:brca gene SemanticType:[gngm] PreferredName:Mutation SemanticType:[genf] PreferredName:Offered SemanticType:[fndg] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:described SemanticType:[idcn] PreferredName:Mutation Carrier SemanticType:[humn] POS:NNS POS:WP POS:VBP POS:VBN POS:TO POS:VB POS:DT POS:NN POS:NN POS:IN POS:NN POS:NN POS:IN POS:CD POS:NN POS:CC POS:JJR POS:, POS:VBN POS:IN POS:NN POS:NNS POS:WDT POS:VBP POS:RB POS:IN POS:NN POS:NN POS:( POS:JJ POS:IN POS:NNP POS:, POS:NNP POS:, POS:CC POS:NNP POS:) POS:, POS:CC POS:WP POS:VBP POS:DT POS:JJ POS:CC POS:VBP POS:JJ POS:IN POS:NNP POS:NN POS:NNS POS:, POS:MD POS:VB POS:VBN POS:JJ POS:NN POS:IN POS:VBD POS:RB POS:IN POS:NNS POS:IN POS:DT POS:NNP POS:NN POS:. 
[sentNum: 290]<Annotation Id="13225" Type="Sentence" StartNode="33119" EndNode="33184">Risk-reduction strategies also may be considered for these women.PreferredName:Risk Reduction SemanticType:[inbe] PreferredName:strategy SemanticType:[menp] PreferredName:consider SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] POS:JJ POS:NNS POS:RB POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NNS POS:. 
[sentNum: 291]<Annotation Id="13226" Type="Sentence" StartNode="33186" EndNode="33393">Other women considered at high risk of development of future cases of breast cancer are those who received thoracic irradiation (typically as a treatment for lymphoma) between the ages 10 years and 30 years. PreferredName:Woman SemanticType:[popg] PreferredName:consider SemanticType:[idcn] PreferredName:High risk of SemanticType:[qlco] PreferredName:Future SemanticType:[tmco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Development of the breasts SemanticType:[fndg] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Receive SemanticType:[qlco] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Lymphoma SemanticType:[neop] PreferredName:Age-Years SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:JJ POS:NNS POS:VBN POS:IN POS:JJ POS:NN POS:IN POS:NN POS:IN POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:VBP POS:DT POS:WP POS:VBD POS:JJ POS:NN POS:( POS:RB POS:IN POS:DT POS:NN POS:IN POS:NN POS:) POS:IN POS:DT POS:JJ POS:CD POS:NNS POS:CC POS:CD POS:NNS POS:. 
[sentNum: 292]<Annotation Id="13227" Type="Sentence" StartNode="33394" EndNode="33620">These women should be advised to receive annual mammography, annual MRI, and screening clinical breast examination every 6–12 months beginning 8–10 years after they received treatment or at age 25 years, whichever occurs last.PreferredName:Woman SemanticType:[popg] PreferredName:To SemanticType:[qlco] PreferredName:Receive SemanticType:[qlco] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Distance vision 6/12 SemanticType:[fndg] PreferredName:month SemanticType:[tmco] PreferredName:Beginning SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Receive SemanticType:[qlco] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Occurrence SemanticType:[tmco] PreferredName:Last SemanticType:[qlco] POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:TO POS:VB POS:JJ POS:JJ POS:, POS:JJ POS:NNP POS:, POS:CC POS:VBG POS:JJ POS:NN POS:NN POS:DT POS:CD POS:NNP POS:CD POS:NNS POS:VBG POS:CD POS:VBD POS:CD POS:NNS POS:IN POS:PRP POS:VBD POS:NN POS:CC POS:IN POS:NN POS:CD POS:NNS POS:, POS:WDT POS:VBZ POS:JJ POS:. 
[sentNum: 293]<Annotation Id="13228" Type="Sentence" StartNode="33622" EndNode="33795">Women with a personal history of high-risk breast biopsy results, including atypical hyperplasia and lobular carcinoma in situ are at increased risk of future breast cancer. PreferredName:Woman SemanticType:[popg] PreferredName:Social and personal history SemanticType:[fndg] PreferredName:High risk of SemanticType:[qlco] PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:Result SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Atypical hyperplasia SemanticType:[patf] PreferredName:Lobular carcinoma in situ of breast SemanticType:[neop] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Future SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:NN POS:NNS POS:, POS:VBG POS:JJ POS:NN POS:CC POS:NN POS:NN POS:IN POS:NN POS:VBP POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:NN POS:. 
[sentNum: 294]<Annotation Id="13229" Type="Sentence" StartNode="33796" EndNode="33963">These women should receive enhanced screening, including annual mammography, clinical breast examination every 6–12 months, and instruction in breast self-examination. PreferredName:Woman SemanticType:[popg] PreferredName:Receive SemanticType:[qlco] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Distance vision 6/12 SemanticType:[fndg] PreferredName:month SemanticType:[tmco] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Breast Self-Examination SemanticType:[diap] POS:DT POS:NNS POS:MD POS:VB POS:VBN POS:NN POS:, POS:VBG POS:JJ POS:NN POS:, POS:JJ POS:NN POS:NN POS:DT POS:CD POS:NNS POS:CD POS:NNS POS:, POS:CC POS:JJ POS:IN POS:NN POS:NN POS:. 
[sentNum: 295]<Annotation Id="13230" Type="Sentence" StartNode="33964" EndNode="34089">Yearly breast MRI also has been recommended for women with a history of lobular carcinoma in situ by some organizations (43). PreferredName:Annual SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:With - dosing instruction fragment SemanticType:[inpr] PreferredName:H/O: carcinoma SemanticType:[fndg] PreferredName:Lobular SemanticType:[qlco] PreferredName:In situ SemanticType:[spco] PreferredName:Organization administrative structures SemanticType:[orgt] POS:JJ POS:NN POS:NNS POS:RB POS:VBZ POS:VBN POS:VBN POS:IN POS:NNS POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:IN POS:NN POS:IN POS:DT POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 296]<Annotation Id="13231" Type="Sentence" StartNode="34090" EndNode="34266">Women with a personal history of ductal carcinoma in situ or invasive breast cancer should be monitored similarly, although MRI is not routinely recommended in this population.PreferredName:Woman SemanticType:[popg] PreferredName:Personal Attribute SemanticType:[orga] PreferredName:H/O: carcinoma SemanticType:[fndg] PreferredName:Ductal SemanticType:[qlco] PreferredName:In situ SemanticType:[spco] PreferredName:Invasive Breast Carcinoma SemanticType:[neop] PreferredName:Preventive monitoring SemanticType:[hlca] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:geographic population SemanticType:[qnco] POS:NNS POS:IN POS:DT POS:JJ POS:NN POS:IN POS:JJ POS:NN POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:NN POS:MD POS:VB POS:VBN POS:RB POS:, POS:IN POS:NNP POS:VBZ POS:RB POS:RB POS:VBN POS:IN POS:DT POS:NN POS:. 
[sentNum: 297]<Annotation Id="13232" Type="Sentence" StartNode="34272" EndNode="34356">Is there an upper age range at which the risks of mammography outweigh the benefits?PreferredName:Upper SemanticType:[spco] PreferredName:Age SemanticType:[orga] PreferredName:Range SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Benefits SemanticType:[qnco] POS:VBZ POS:EX POS:DT POS:JJ POS:NN POS:NN POS:IN POS:WDT POS:DT POS:NNS POS:IN POS:NNP POS:VBP POS:DT POS:NNS POS:. 
[sentNum: 298]<Annotation Id="13233" Type="Sentence" StartNode="34358" EndNode="34418">A consensus of recommendations on this issue does not exist. PreferredName:Consensus SemanticType:[socb] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Problem SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Exist SemanticType:[cnce] POS:DT POS:NN POS:IN POS:NNS POS:IN POS:DT POS:NN POS:VBZ POS:RB POS:VB POS:. 
[sentNum: 299]<Annotation Id="13234" Type="Sentence" StartNode="34419" EndNode="34665">Medical comorbidity and life expectancy should be considered in a breast cancer screening program for women aged 75 years or older because the benefit of screening mammography decreases compared with the harms of overtreatment with advancing age. PreferredName:Medical SemanticType:[ftcn] PreferredName:Comorbidity SemanticType:[idcn] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:consider SemanticType:[idcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Program SemanticType:[phsu] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Decrease SemanticType:[qnco] PreferredName:Comparison SemanticType:[acty] PreferredName:Advance SemanticType:[medd] PreferredName:Age SemanticType:[orga] POS:JJ POS:NN POS:CC POS:NN POS:NN POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:NN POS:NN POS:NN POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:VBZ POS:VBN POS:IN POS:DT POS:NNS POS:IN POS:NN POS:IN POS:VBG POS:NN POS:. 
[sentNum: 300]<Annotation Id="13235" Type="Sentence" StartNode="34666" EndNode="34804">Women aged 75 years or older should, in consultation with their physicians, decide whether or not to continue mammographic screening (17).PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Present SemanticType:[qnco] PreferredName:Consultation SemanticType:[hlca] PreferredName:Physicians SemanticType:[prog] PreferredName:Negation SemanticType:[ftcn] PreferredName:Continuous SemanticType:[idcn] PreferredName:Screening mammography SemanticType:[topp] POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:MD POS:, POS:IN POS:NN POS:IN POS:PRP$ POS:NNS POS:, POS:VB POS:IN POS:CC POS:RB POS:TO POS:VB POS:JJ POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 301]<Annotation Id="13236" Type="Sentence" StartNode="34806" EndNode="34947">Figure 1 illustrates the progressively increasing incidence and mortality rates of invasive breast cancer by race and age up to 84 years (3). PreferredName:Increasing SemanticType:[ftcn] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Invasive SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Racial group SemanticType:[popg] PreferredName:Age-Years SemanticType:[tmco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:NN POS:CD POS:VBZ POS:DT POS:RB POS:JJ POS:NN POS:CC POS:NN POS:NNS POS:IN POS:JJ POS:NN POS:NN POS:IN POS:NN POS:CC POS:NN POS:RP POS:TO POS:CD POS:NNS POS:( POS:CD POS:) POS:. 
[sentNum: 302]<Annotation Id="13237" Type="Sentence" StartNode="34948" EndNode="35064">Most of the screening mammography clinical trials had an upper age limit criteria ranging from 64 years to 74 years. PreferredName:Most SemanticType:[qnco] PreferredName:Mammography SemanticType:[diap] PreferredName:Trial Screening SemanticType:[resa] PreferredName:Upper SemanticType:[spco] PreferredName:Age SemanticType:[orga] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:criteria SemanticType:[inpr] PreferredName:Range SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:year SemanticType:[tmco] POS:JJS POS:IN POS:DT POS:NN POS:NN POS:JJ POS:NNS POS:VBD POS:DT POS:JJ POS:NN POS:NN POS:NNS POS:VBG POS:IN POS:CD POS:NNS POS:TO POS:CD POS:NNS POS:. 
[sentNum: 303]<Annotation Id="13238" Type="Sentence" StartNode="35065" EndNode="35234">However, a meta-analysis concluded that screening mammography in women aged 70–79 years is moderately cost-effective and yields a small increase in life expectancy (54).PreferredName:Meta Analysis (statistical procedure) SemanticType:[resa] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Moderation SemanticType:[qlco] PreferredName:Cost Effectiveness SemanticType:[qnco] PreferredName:Small SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Life Expectancy SemanticType:[grpa] POS:RB POS:, POS:DT POS:NNS POS:VBD POS:IN POS:VBG POS:RB POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:VBZ POS:RB POS:JJ POS:CC POS:VBZ POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:( POS:CD POS:) POS:. 
[sentNum: 304]<Annotation Id="13239" Type="Sentence" StartNode="35236" EndNode="35288">Female Breast Cancer - Incidence and Mortality RatesPreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Mortality Vital Statistics SemanticType:[qnco] POS:JJ POS:NNP POS:NNP POS:: POS:NNP POS:CC POS:NNP POS:NNP 
[sentNum: 305]<Annotation Id="13240" Type="Sentence" StartNode="35290" EndNode="35332">Summary of Recommendations and ConclusionsPreferredName:Summary (document) SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Conclusion SemanticType:[idcn] POS:NN POS:IN POS:NNS POS:CC POS:NNS 
[sentNum: 306]<Annotation Id="13241" Type="Sentence" StartNode="35334" EndNode="35432">The following recommendations are based on limited and inconsistent scientific evidence (Level B):PreferredName:Following SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Inconsistent SemanticType:[qlco] PreferredName:Science SemanticType:[ocdi] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Disease classification level SemanticType:[clas] POS:DT POS:VBG POS:NNS POS:VBP POS:VBN POS:IN POS:JJ POS:CC POS:JJ POS:JJ POS:NN POS:( POS:NNP POS:NNP POS:) POS:: 
[sentNum: 307]<Annotation Id="13242" Type="Sentence" StartNode="35438" EndNode="35678">Based on the incidence of breast cancer, the sojourn time for breast cancer growth, and the potential reduction in breast cancer mortality, the College recommends that women aged 40 years and older be offered screening mammography annually.PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:incidence of cases SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Sojourn SemanticType:[orch, phsu] PreferredName:Time SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:growth aspects SemanticType:[phsf] PreferredName:Potential SemanticType:[qlco] PreferredName:Reduction - action SemanticType:[topp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:College SemanticType:[mnob] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Offered SemanticType:[fndg] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Annual SemanticType:[tmco] POS:VBN POS:IN POS:DT POS:NN POS:IN POS:NN POS:NN POS:, POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NN POS:, POS:CC POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NN POS:, POS:DT POS:NNP POS:VBZ POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:VB POS:VBN POS:VBG POS:RB POS:RB POS:. 
[sentNum: 308]<Annotation Id="13243" Type="Sentence" StartNode="35680" EndNode="35772">The following recommendations are based primarily on consensus and expert opinion (Level C):PreferredName:Following SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Consensus SemanticType:[socb] PreferredName:Expert Opinion SemanticType:[cnce] PreferredName:Disease classification level SemanticType:[clas] POS:DT POS:VBG POS:NNS POS:VBP POS:VBN POS:RB POS:IN POS:NN POS:CC POS:NN POS:NN POS:( POS:NNP POS:NNP POS:) POS:: 
[sentNum: 309]<Annotation Id="13244" Type="Sentence" StartNode="35778" EndNode="35869">Clinical breast examination should be performed annually for women aged 40 years and older.PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Performed SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] POS:JJ POS:NN POS:NN POS:MD POS:VB POS:VBN POS:RB POS:IN POS:NNS POS:VBN POS:CD POS:NNS POS:CC POS:JJR POS:. 
[sentNum: 310]<Annotation Id="13245" Type="Sentence" StartNode="35875" EndNode="35964">For women aged 20–39 years, clinical breast examinations are recommended every 1–3 years.PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Clinical Breast Examination SemanticType:[topp] PreferredName:Recommendation SemanticType:[idcn] PreferredName:1+ Score SemanticType:[qnco] PreferredName:year SemanticType:[tmco] POS:IN POS:NNS POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:, POS:JJ POS:NN POS:NNS POS:VBP POS:VBN POS:DT POS:CD POS:NNP POS:CD POS:NNS POS:. 
[sentNum: 311]<Annotation Id="13246" Type="Sentence" StartNode="35970" EndNode="36053">Breast self-awareness should be encouraged and can include breast self-examination. PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Self awareness SemanticType:[menp] PreferredName:Include (action) SemanticType:[acty] PreferredName:Breast Self-Examination SemanticType:[diap] POS:NN POS:NN POS:MD POS:VB POS:VBN POS:CC POS:MD POS:VB POS:NN POS:NN POS:. 
[sentNum: 312]<Annotation Id="13247" Type="Sentence" StartNode="36054" EndNode="36134">Women should report any changes in their breasts to their health care providers.PreferredName:Woman SemanticType:[popg] PreferredName:Reporting SemanticType:[hlca] PreferredName:Breast changes SemanticType:[fndg] PreferredName:Health Personnel SemanticType:[prog] POS:NNS POS:MD POS:VB POS:DT POS:NNS POS:IN POS:PRP$ POS:NNS POS:TO POS:PRP$ POS:NN POS:NN POS:NNS POS:. 
[sentNum: 313]<Annotation Id="13248" Type="Sentence" StartNode="36140" EndNode="36286">Women should be educated on the predictive value of screening mammography and the potential for false-positive results and false-negative results. PreferredName:Woman SemanticType:[popg] PreferredName:Educational process of instructing SemanticType:[edac] PreferredName:Predictive Value SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Potential SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] POS:NNP POS:MD POS:VB POS:VBN POS:IN POS:DT POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:CC POS:DT POS:NN POS:IN POS:JJ POS:NNS POS:CC POS:JJ POS:NNS POS:. 
[sentNum: 314]<Annotation Id="13249" Type="Sentence" StartNode="36287" EndNode="36415">Women should be informed of the potential for additional imaging or biopsies that may be recommended based on screening results.PreferredName:Woman SemanticType:[popg] PreferredName:Informed SemanticType:[qlco] PreferredName:Potential SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Diagnostic Imaging SemanticType:[diap] PreferredName:Biopsy SemanticType:[diap] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] POS:NNS POS:MD POS:VB POS:VBN POS:IN POS:DT POS:NN POS:IN POS:JJ POS:NN POS:CC POS:NNS POS:WDT POS:MD POS:VB POS:VBN POS:VBN POS:IN POS:VBG POS:NNS POS:. 
[sentNum: 315]<Annotation Id="13250" Type="Sentence" StartNode="36421" EndNode="36704">Women who are estimated to have a lifetime risk of breast cancer of 20% or greater, based on risk models that rely largely on family history (such as BRCAPRO, BODACEA, or Claus), but who are either untested or test negative for BRCA gene mutations, can be offered enhanced screening.PreferredName:Woman SemanticType:[popg] PreferredName:Estimated SemanticType:[qnco] PreferredName:To SemanticType:[qlco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Greater SemanticType:[qnco] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Model SemanticType:[inpr] PreferredName:Family History Domain SemanticType:[idcn] PreferredName:BRCAPRO SemanticType:[inpr] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Negative SemanticType:[qlco] PreferredName:brca gene SemanticType:[gngm] PreferredName:Mutation SemanticType:[genf] PreferredName:Offered SemanticType:[fndg] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:NNS POS:WP POS:VBP POS:VBN POS:TO POS:VB POS:DT POS:NN POS:NN POS:IN POS:NN POS:NN POS:IN POS:CD POS:NN POS:CC POS:JJR POS:, POS:VBN POS:IN POS:NN POS:NNS POS:WDT POS:VBP POS:RB POS:IN POS:NN POS:NN POS:( POS:JJ POS:IN POS:NNP POS:, POS:NNP POS:, POS:CC POS:NNP POS:) POS:, POS:CC POS:WP POS:VBP POS:DT POS:JJ POS:CC POS:VBP POS:JJ POS:IN POS:NNP POS:NN POS:NNS POS:, POS:MD POS:VB POS:VBN POS:JJ POS:NN POS:. 
[sentNum: 316]<Annotation Id="13251" Type="Sentence" StartNode="36710" EndNode="36804">Breast MRI is not recommended for screening women at average risk of developing breast cancer.PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:At risk SemanticType:[qlco] PreferredName:Average SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:NNP POS:NNP POS:VBZ POS:RB POS:VBN POS:IN POS:VBG POS:NNS POS:IN POS:JJ POS:NN POS:IN POS:VBG POS:NN POS:NN POS:. 
[sentNum: 317]<Annotation Id="13252" Type="Sentence" StartNode="36810" EndNode="36947">For women who test positive for BRCA1 and BRCA2 mutations, enhanced screening should be recommended and risk reduction methods discussed.PreferredName:Woman SemanticType:[popg] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Positive Finding SemanticType:[fndg] PreferredName:BRCA2 Gene Mutation SemanticType:[comd] PreferredName:Enhance (action) SemanticType:[acty] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Risk Reduction SemanticType:[inbe] PreferredName:Methods aspects SemanticType:[inpr] POS:IN POS:NNS POS:WP POS:VBP POS:JJ POS:IN POS:NNP POS:CD POS:CC POS:NNP POS:CD POS:NNS POS:, POS:JJ POS:NN POS:MD POS:VB POS:VBN POS:CC POS:NN POS:NN POS:NNS POS:VBN POS:. 
